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Peripherally-restricted kappa opioid receptor (KOR) agonists are emerging as a novel treatment 
for pain and itch conditions and have shown efficacy in several recent clinical trials. One primary 
site of action is thought to be at KORs on primary afferent nerves that innervate the body. Yet, 
the subtypes of primary afferent somatosensory neurons that express the kappa opioid receptor 
remain undefined. Using a newly developed KOR-cre knockin allele, viral tracing, and single-
cell RT-PCR we discovered that that KOR is expressed in a specific subset of peptidergic 
afferents. This subset targeted multiple tissue types and expressed higher levels of transcripts 
known to be involved in neurogenic inflammation. Consistent with this, peripherally-restricted 
KOR agonists inhibited behavioral responses to chemical pain and itch stimuli, but not acute heat 
stimuli, and also decreased mechanical hypersensitivity following an incision injury. 
Unexpectedly, we also found that KOR is expressed in subsets of primary afferents that form 
lanceolate or circumferential endings around hair follicles, suggesting an unappreciated role for 
KOR signaling in the modulation of low-threshold mechanosensation. At a functional level, 
genetically-labeled afferents showed inhibition of voltage-gated calcium current in response to 
kappa agonists, and optogenetic experiments revealed that dynorphin inhibited evoked-EPSCs 
from the central terminals of KOR-expressing afferents. These experiments provide key insight 
for the rationale use of peripherally-restricted KOR agonists for the modulation of inflammatory 
pain, itch, and potentially mechanical allodynia. 
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1.0  GENERAL INTRODUCTION 
One of the earliest opioid-based treatments for pain was developed by Paracelsus, the 16th 
century Swiss-German alchemist, who is known today as the father of modern toxicology. 
Paracelsus referred to this opium-containing tincture as Laudanum, from the latin verb laudare, 
to praise. The name was adopted as a general term for any mixture of opium and alcohol, and 
gained popularity through use by the English physician Thomas Sydenham in the 1600s. Though 
a proponent of its use for allaying pain, he warned of the dangers overuse could bring. Even 
Sydenham himself tried to limit use of the drug in his practices (Davenport-Hines, 2003) likely 
because he was wary of the very same problems that too often accompany prescription opioid 
use today. 
As Paracelsus and Sydenham observed centuries ago, opioids drugs targeting the mu 
opioid receptor (MOR) can be potent analgesics and, as such, have been the focus of decades of 
modern research aimed at developing better treatments for pain. Mu opioid receptor (MOR) 
agonists, such as morphine, remain among the most widely used treatments for various acute and 
chronic pain conditions (H. S. Smith & Peppin, 2014). While often effective at relieving pain, 
MOR agonists are frequently accompanied by deleterious side effects such as respiratory 
depression, sedation, nausea, constipation, and the development of tolerance (Boom et al., 2012) 
(Bailey & Connor, 2005). In addition, millions of Americans have been estimated to suffer from 
substance abuse stemming from mu agonist-based prescription pain relievers due to their high 
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addictive potential (D. E. Smith, 2017). Yet the class of opioid molecules and their receptors are 
comprised of several primary subtypes including mu, delta, and kappa (Kieffer & Gaveriaux-
Ruff, 2002). As a result, the potential utility of other classes of opioids have been the topic of 
much interest.  
For several decades, the kappa opioid receptor (KOR) has been a promising therapeutic 
target for pain (for review, see (Millan, 1990; Vanderah, 2010)) and itch (Stull, Lavery, & 
Yosipovitch, 2016). However, the clinical use of drugs targeting KORs have not been widely 
adopted. As with MORs, KORs are expressed throughout the body and therefore systemic drugs 
can have undesired effects that can limit their use. Several approaches to design KOR agonists 
that specifically target the analgesic and/or antipruritic effects are being investigated, such as 
biased agonists and peripherally-restricted agonists. Yet if these approaches are to be widely 
adopted, it is important that we understand what cell types express KOR. This understanding can 
inform how the opioid system is designed to modulate somatosensory information in naïve 
conditions, how that changes following an injury or disease, and how best to use 
pharmacological interventions to ameliorate pain and itch that arise in particular situations. 
1.1 KOR MODULATION OF THE SOMATOSENSORY SYSTEM 
1.1.1 KOR signaling pathways 
The KOR is a member of the seven-transmembrane domain G-protein coupled receptor (GPCR) 
family. KORs are activated by the endogenous opioid dynorphin, which has a higher binding 
affinity for KOR over other opioid receptors (Chavkin & Goldstein, 1981); (Chavkin, James, & 
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Goldstein, 1982); (Huidobro-Toro & Way, 1982). Binding to the KOR by its endogenous ligand, 
dynorphin, or exogenous ligands, leads to a conformational change and subsequent dissociation 
of Gi/o coupled Gα and Gβγ subunits.  
Opioid receptor activation initiates signaling pathways in which Kir3, the inwardly 
rectifying potassium channel, is activated through a G protein, pertussis toxin-sensitive 
mechanism (Al-Hasani & Bruchas, 2011). This effect has been demonstrated in model cell 
systems (Ikeda, Kobayashi, Ichikawa, Usui, & Kumanishi, 1995); (Henry, Grandy, Lester, 
Davidson, & Chavkin, 1995); (Ma, Miller, Kuznetsov, & Philipson, 1995); (Ueda, Miyamae, 
Fukushima, Watanabe, & Misu, 1995); (Ulens, Daenens, & Tytgat, 1999) and in spinal cord 
neurons (Grudt & Williams, 1993) following application of a KOR agonist. However, direct 
evidence for a KOR driven effect on Kir3-mediated current in primary afferent neurons is mixed 
(Marker, Lujan, Loh, & Wickman, 2005); (Fan & Crain, 1995). There are many studies 
demonstrating that KOR activation inhibits influx of voltage-gated calcium current (VGCC) 
(Werz & Macdonald, 1984); (Macdonald & Werz, 1986); (Su, Wachtel, & Gebhart, 1998) 
through high-threshold (N-, P-, and Q-type) voltage-gated calcium channels (Wiley, Moises, 
Gross, & MacDonald, 1997); (Moises, Rusin, & Macdonald, 1994) by reducing the ‘willingness’ 
of channel opening at a given voltage (Bean, 1989); (Gross, Moises, Uhler, & Macdonald, 1990). 
Although these recordings were performed on the cell body of dissociated dorsal root ganglion 
(DRG) neurons, these results suggest that KOR activation decreases calcium-dependent 
neurotransmitter release from axon terminals. In addition to regulating ion channels, KORs also 
inhibit adenylyl cyclase (AC) and therefore decrease cyclic adenosine monophosphate (cAMP) 
levels (Grudt & Williams, 1993); (Stein & Zollner, 2009). Inhibition of AC and cAMP 
production is thought to contribute to the antinociceptive properties of several drugs, including 
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morphine, as cAMP can increase excitability of sensory neurons through protein kinase A 
(PKA)-dependent phosphorylation of ion channels such as Nav1.8 and TRPV1 (Pierre, 
Eschenhagen, Geisslinger, & Scholich, 2009). Overall, the effect of KOR activation on sensory 
neurons is to decrease neuronal excitability. 
Following sustained KOR activation, the receptor is phosphorylated by G-protein 
coupled receptor kinase3 (GRK3) leading to βarrestin-recruitment. Recent studies have shown 
that this βarrestin bound receptor is not necessarily inactive, as previously thought, and can lead 
to mitogen-activated protein kinase (MAPK) signaling pathways including ERK ½, JNK 1-3, 
and p38α, which can impact gene expression and protein phosphorylation. The potential 
downstream effects of βarrestin-mediated KOR signaling on cell function are still being 
investigated (Bruchas & Chavkin, 2010). 
In summary, the activation of the KOR has been shown to have effects that generally 
decrease neuronal excitability and neurotransmission, and recent work is starting to investigate 
how KOR activation of downstream intracellular signaling pathways can affect gene regulation 
and protein signaling.  
1.1.2 Preclinical evidence for KOR involvement in analgesia 
Previous pharmacological work has established KOR agonists as having analgesic properties in 
several preclinical pain models using rodents. One of the earliest, more specific KOR agonists 
developed, U50,488, has been shown to be analgesic in multiple acute pain assays using either 
noxious thermal, mechanical, or chemical stimuli (Vonvoigtlander, Lahti, & Ludens, 1983). 
Systemic administration of non-peptide KOR agonist CI-977 increased mechanical thresholds in 
the tail clip assay and decreased responses in a model of chemically induced visceral pain 
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(Hunter et al., 1990). Systemically administered KOR agonist U69,593 decreased thermal 
sensitivity in the Hargreaves’ test (Schepers, Mahoney, Gehrke, & Shippenberg, 2008). These 
studies show that systemically administered KOR agonists can generate analgesia in multiple 
assays testing different somatosensory modalities indicating that these drugs may be useful to 
treat a wide range of clinical pain conditions. As systemically administered KOR agonists likely 
act on KORs throughout the body, several groups have also investigated the effects of KOR 
agonist application to specific sites within the CNS. Intrathecal administration of KOR agonists 
decreased writhing in response to an intraperitoneal (IP) injection of an acidic compound 
(Porreca, Mosberg, Omnaas, Burks, & Cowan, 1987). Intracerebroventricular, intrathecal 
administration of the dynorphin analog E-2078 was analgesic in the tail pinch test, tail flick test, 
and the formalin test (Nakazawa, Furuya, Kaneko, & Yamatsu, 1991). These data suggest that 
KOR signaling throughout several regions in the CNS, even at the spinal level, has analgesic 
effects. KOR agonists have also been shown to be analgesic in preclinical models using non-
human primates. Dykstra et al. (Dykstra, Gmerek, Winger, & Woods, 1987) reported a decrease 
in tail withdrawal latency to a noxious thermal stimulus after systemic treatment with U50,488; 
Sukhtankar et al. (Sukhtankar, Lee, Rice, & Ko, 2014) have reported analgesic effects of 
systemic U50,488 in an acute thermal assay or in carrageenan-induced thermal hypersensitivity; 
and Endoh et al. (Endoh et al., 2001) observed an increase in withdrawal latency to a noxious 
thermal stimulus following systemic nalfurafine administration. These preclinical studies in non-
human primates support the translation of KOR agonist-mediated analgesia from rodent models 
to potential clinical utility in humans.  
Pharmacological studies blocking KOR signaling have shown complementary results in 
preclinical pain assays. Systemic administration of norBNI, a KOR antagonist, aggravated 
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thermal and mechanical hypersensitivity in the hind paw of mice following an intraplantar 
injection of complete Freund’s adjuvant (CFA) (Schepers, Mahoney, Gehrke, et al., 2008). 
Systemic, intrathecal, or rostral ventromedial medulla (RVM) injection of norBNI also decreased 
mechanical thresholds of the non-inflamed paw which suggests the kappa opioid system may 
have a particularly strong effect on mechanical sensitivity (Schepers, Mahoney, Gehrke, et al., 
2008). Intrathecal administration of norBNI prevented the decrease in withdrawal latency in the 
tail flick assay that is normally observed following a preconditioning noxious thermal stimulus 
of the hind paw suggesting that KORs at the spinal level are involved in stress-induced analgesia 
(Yashpal, Pitcher, & Henry, 1995). Intrathecal norBNI also increased flinching in response to 
intraplantar formalin injection (Ossipov et al., 1996), as did intrathecal pre-treatment with 
dynorphin antiserum (Ossipov et al., 1996); (Wu, Hung, Mizoguchi, Nagase, & Tseng, 2002). In 
a model of neuropathic pain, systemic treatment with KOR antagonists norBNI increased 
mechanical and thermal hyperalgesia observed after nerve injury (M. Xu et al., 2004). These 
studies using KOR antagonists indicate that the endogenous kappa opioid system is engaged 
following an injury and acts to mitigate hypersensitivity. In sum, there is substantial evidence 
that activating KOR or blocking KOR signaling can bidirectionally modulate nociception in 
preclinical models.   
In addition to pharmacological experiments, the role of KOR in antinociception is also 
supported by studies using KOR knockout (KO) mice. KOR KO mice show increased 
responsiveness to an intraperitoneal injection of an acidic compound. Yet, KOR KO mice 
respond similarly to control mice in behavioral models of acute inflammatory, mechanical, and 
thermal pain. This may be due to compensatory developmental alterations, as the mice used in 
this study had been lacking KOR expression throughout development. However, the increase in 
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thermal threshold observed in control mice after administration of KOR agonist U50,488 was not 
observed in KOR KO mice (Simonin et al., 1998), indicating that KORs are critical for U50,488-
mediated antinociception. In a separate study, KOR KO mice showed exaggerated mechanical 
and thermal hypersensitivity in the CFA model of inflammatory pain (Schepers, Mahoney, & 
Shippenberg, 2008). Consistent with pharmacological experiments that indicate KOR antagonists 
are increase nociception, KOR gene knockout mice show exacerbated nociceptive responses, 
particularly in response chemical stimuli or in an inflammatory state. 
Together, pharmacological studies and studies in KOR KO mice provide strong evidence 
that the kappa opioid system is involved in pain processing, with the dominant effect of KOR 
activation being antinociception. Although some studies have shown a pronociceptive effect of 
dynorphin signaling evidence suggests that this is through a non-opioid receptor mediated 
mechanism (for review see, (Podvin, Yaksh, & Hook, 2016)). The contribution of KORs on 
specific neuron types or in different regions of the pain pathway and how each might contribute 
to mediating distinct modalities of pain is less clear. This is important to understand for several 
reasons. First, to aid our understanding in the context of how the opioid system is organized to 
regulate somatosensation. Second, to better understand the context for the development of 
efficacious KOR-based therapies for the treatment of different pain conditions particularly 
because the changes in the nervous system following different types of injury or disease are 
unique. 
1.1.3 Preclinical evidence for KOR involvement in antipruritus 
In addition to a role in nociceptive processing, the kappa opioid system also plays a role in 
pruritoception. Some of the first connections between the kappa opioid system and itch 
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processing was reported in ‘kappa-dependent’ monkeys that had been given multiple injections 
of KOR agonists. Following withdrawal from KOR agonist injections and subsequent challenge 
with non-selective opioid receptor antagonist, naloxone, these monkeys showed elevated levels 
of scratching all over their body (Cowan, 1973); (Gmerek, Dykstra, & Woods, 1987); (Cowan, 
Kehner, & Inan, 2015). This observation suggests that the kappa opioid system is involved in the 
tonic suppression of itch sensation. Later, it was observed that KOR agonists decreased 
scratching behavior caused by the peptide bombesin in rats (Gmerek & Cowan, 1988). Since that 
time, the KOR agonist nalfurafine (also called TRK-80) has been shown to decrease scratching 
in preclinical rodent models of acute itch that use intradermal injections of pruritogens that cause 
scratching through either the histamine-mediated pathway or the non-histamine-mediated 
pathway (Togashi et al., 2002); (Kardon et al., 2014); (Y. Wang et al., 2005); (Inan & Cowan, 
2004); (Umeuchi et al., 2003). Similar antipruritic effects have been observed using the KOR 
agonist U50,488 (Kardon et al., 2014); (Kamei & Nagase, 2001); (Morgenweck, Frankowski, 
Prisinzano, Aube, & Bohn, 2015). Nalfurafine has been shown to reduce scratching in preclinical 
rodent models of chronic itch (Nakao et al., 2008); (Inan & Cowan, 2006); (Kardon et al., 2014). 
In a rat model of cholestasis, the magnitude of KOR-driven G protein signaling was significantly 
reduced in the hypothalamus and serum dynorphin levels were lower in cholestatic rats 
compared to controls, leading the authors to suggest that an imbalance in KOR signaling 
contributes to cholestatic pruritus (Inan & Cowan, 2005). The modulation of the KOR system 
has a similar effect on scratching in nonhuman primate models. Nalfurafine and U50,488 have 
been shown to decrease intravenous morphine-induced scratching (Wakasa et al., 2004), 
suggesting that these drugs administered systemically can decrease itch sensation. Similar results 
were observed in monkeys. Following spinal delivery of KOR agonist dynorphin A inhibited β-
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endorphin (an endogenous MOR agonist)- and gastrin-releasing peptide (GRP)-induced 
scratching (Lee & Ko, 2015). Opposite effects are observed with KOR antagonists. When 
norBNI is injected intradermally into the rostral back, it elicits scratching behavior in mice like 
that of pruritogen-induced scratching (Kamei & Nagase, 2001). KOR antagonists norBNI and 
5’GNTI elicit acute episodes of scratching when injected subcutaneously in the neck area. This 
effect was decreased in KOR KO mice (Morgenweck et al., 2015) indicating that in wild type 
mice the endogenous kappa opioid system is regulating pruritoceptive sensitivity. In summary, 
similar to KOR signaling in analgesia, activation of KOR signaling during pruritus decreases 
scratching responses, but blocking KOR activation can lead to an elevated pruritoception. 
The studies discussed above provide strong evidence that activation of the KOR can 
induce antipruritus in multiple experimental paradigms. As many of the studies discussed above 
used systemic administration or constitutive KO models, the contribution of KOR expressed in 
different cell types or regions of the nervous system cannot be separated which, as discussed 
below, is important for informing development of kappa opioid-based therapeutics and 
understanding how the nervous system uses opioids at different points in somatosensory 
processing.  
1.2 STRATEGIES TO IMPROVE UTILITY OF KOR AGONISTS IN A CLINICAL 
SETTING 
While MOR pain relievers’ act to decrease both sensory transmission of pain and the affective, 
unpleasant component of pain, central KORs modulate affect in the opposite direction. KOR 
agonists can induce conditioned place aversion in rodent models (Zhang, Butelman, Schlussman, 
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Ho, & Kreek, 2005); (Chefer, Backman, Gigante, & Shippenberg, 2013); Tejeda (Tejeda et al., 
2013), and in humans are dysphoric and anxiogenic (Kumor et al., 1986); (Pfeiffer, Brantl, Herz, 
& Emrich, 1986); (Walsh, Strain, Abreu, & Bigelow, 2001) which is thought to be a result of 
decreased dopamine release in reward and motivation circuits in the brain (for review, see 
(Shippenberg, Chefer, Zapata, & Heidbreder, 2001)). KOR agonists can have strong sedative 
effects (Leighton, Hill, & Hughes, 1988); (Dykstra et al., 1987) and cause diuresis (Leander, 
1983); (Blackburn, Borkowski, Friend, & Rance, 1986); (Dykstra et al., 1987). The kappa opioid 
system plays a central role not only in modulating somatosensory information but also in the 
regulation of mood, stress, and reward seeking behaviors. Thus, KOR agonists have not been 
widely used to treat pain and/or itch conditions due to these adverse properties; patients’ 
symptoms may be mitigated, but their emotional states are significantly worsened. In an effort to 
avoid the dysphoric, anxiogenic, and sedative effects of KOR agonists, two different strategies 
have been adopted; one of which is to use a biased signaling agonist and the other is to use a 
peripherally-restricted agonist. 
1.2.1 Two main approaches to specifically target KORs for analgesia/antipruritus 
Several studies by Chavkin and colleagues have shown using rodent models that p38 MAPK 
activation via the βarrestin signaling pathway of the KOR is required for the aversive, dysphoric 
effects of KOR agonists (Bruchas et al., 2007); (Land et al., 2009); (Ehrich et al., 2015), while 
the G protein signaling pathways underlie analgesic effects (Bruchas et al., 2007). These 
observations have led to the suggestion that biased, or functionally selective, KOR agonists that 
do not engage βarrestin may be useful as analgesics without inducing dysphoria (Bruchas & 
Chavkin, 2010). The Roth laboratory has studied and characterized the bias of many KOR 
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ligands (White et al., 2014), and has used this information to investigate the signaling pathways 
underlying various effects of KOR agonists in a preclinical rodent model. Using a strongly G 
protein biased KOR ligand, RB-64, White et al. (White et al., 2015) observed a reduction in 
withdrawal latency in the hotplate test and conditioned place aversion to RB-64, but did not 
observe locomotor deficits or a change in intracranial self-stimulation (ICSS; a model of 
dysphoria) when the drug was administered systemically. These data support the possibility of 
using a G protein biased agonists to target analgesic effects of KOR signaling, but RB-64 still 
caused conditioned place aversion. This study suggests that further investigation of the emotional 
effects of these types of drugs is warranted, as the effect of biased signaling may vary depending 
upon the area of the nervous system. 
This biased signaling approach has shown promise in preclinical rodent models of itch as 
well. G protein biased agonists Isoquinolinone 2.1 reduced norBNI induced scratching to a 
similar extent as U50,488 (which is a very slightly βarrestin biased agonist). U50,488 decreased 
scratching in both wild-type and βarr2-KO mice suggesting antipruritic effects of KOR agonists 
may not require βarrestin signaling. (Morgenweck et al., 2015). Further, G-protein biased agonist 
triazole 1.1 reduced chloroquine-induced scratching and increased withdrawal latency in the tail 
flick assay without causing sedation in a locomotor assay or suppressing ICSS (an assay of 
dysphoria) (Brust et al., 2016). Collectively, these data support the idea that analgesic and 
antipruritic effects of KOR agonists could be accomplished with a G protein biased ligand while 
possibly mitigating negative psychoactive effects. However, this hypothesis remains to be tested 
in the clinic. 
Another approach to targeting the analgesic and / or antipruritic effects of KOR agonists 
is to design and administer ligands that do not cross the blood brain barrier (BBB). Targeting 
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peripheral KOR has the advantage of avoiding activation of CNS KORs that mediate sedative 
and dysphoric effects. Proof of principle for this approach is evident in reports from several 
groups have shown that that small volume, site-directed, systemically inactive doses of KOR 
agonists can have analgesic effects in rodent models of inflammatory pain (Auh & Ro, 2012); 
(Cunha et al., 2012); (Obara et al., 2009), (Binder et al., 2001); (Keita, Kayser, & Guilbaud, 
1995); (Antonijevic, Mousa, Schafer, & Stein, 1995); (Stein, Millan, Shippenberg, Peter, & 
Herz, 1989). Using systemically administered peripherally-restricted KOR agonists, numerous 
studies have observed reductions in nociceptive responses in preclinical rodent models. Early 
studies with the peripherally-restricted KOR agonist asimadoline showed a reduction in pain-
related behavior in an adjuvant arthritis model (Binder & Walker, 1998). Several studies using 
peripherally-restricted KOR agonist ICI204,488 observed efficacy in reducing behavioral 
responses in acute models of inflammation such as the formalin test (Rogers et al., 1992); 
(Barber et al., 1994) and the abdominal writhing test (Barber et al., 1994); (Negus, O'Connell, 
Morrissey, Cheng, & Rice, 2012), as well as in in reducing hypersensitivity in neuropathic pain 
models (Caram-Salas et al., 2007); (Keita et al., 1995). Studies using tetrapeptide peripherally-
restricted KOR agonists (FE200041, FE200665, or FE200666) have shown that these 
compounds reduce acetic-acid induced writhing, nociceptive responses in the formalin test, acute 
thermal sensitivity and mechanical hypersensitivity following CFA injection (Vanderah et al., 
2004); (Vanderah et al., 2008); (Binder et al., 2001). 
Multiple clinical studies have explored the potential of peripherally-restricted KOR agonists 
for the treatment of pain. Eluxadoline, a mixed MOR / KOR agonist and DOR antagonist that 
acts primarily in the periphery (Wade et al., 2012), is a recent FDA-approved treatment for 
irritable bowel syndrome with diarrhea (IBS-D) that is efficacious and has a low abuse potential 
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(Levy-Cooperman et al., 2016); (Lembo et al., 2016); (Fant, Henningfield, Cash, Dove, & 
Covington, 2017). Asimadoline, another peripherally-acting KOR agonist, has been shown to be 
well tolerated in humans, but a Phase III clinical trial with IBS patients was not completed and 
clinical trials for arthritis treatment were started but did not progress past phase II (Camilleri, 
2008); (Mangel & Hicks, 2012); (Barber & Gottschlich, 1997). Enandoline, a peripherally acting 
KOR agonist, has been used in several clinical trials for the treatment of post-surgical pain but 
was observed to have use-limiting neuropsychiatric effects at analgesic doses suggesting that at 
these doses the drug crossed the blood-brain barrier (Pande et al., 1996); (Walsh et al., 2001). 
The development of several tetrapeptide, peripherally-restricted KOR agonists have shown 
promise in clinical trials. Clinical trials from the pharmaceutical company that manufactures 
CR845, Cara Therapeutics, are testing the therapeutic efficacy of the peripheral KOR agonist in 
osteoarthritis pain and in various post-operative pain settings. Some of these trials have shown 
promising results; a significant reduction in pain scores compared to placebo (ClinicalTrials.gov, 
2015b); (ClinicalTrials.gov, 2015a). However, the mechanism of a peripherally-restricted KOR 
agonist-induced reduction in post-operative pain has not been investigated.  
Cowan and colleagues have shown that peripherally-restricted KOR agonists can 
decrease itch sensation in preclinical rodent models (Inan & Cowan, 2004); (Cowan et al., 2015) 
suggesting that peripheral KOR agonist have effects on multiple somatosensory modalities. 
Clinically, new therapies for itch are advancing rapidly, one of which is the above mentioned 
KOR agonist nalfurafine (also known as TRK-80). Nalfurafine is clinically approved in Japan to 
treat uremic pruritus and cholestatic pruritus, and is currently in phase 2 clinical trials to treat 
prurigo nodularis, a condition characterized by pruritic nodules on the skin. Butorphanol, a 
mixed KOR agonist/MOR antagonist, has also shown efficacy at reducing itch in patients with 
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intractable pruritus. Both of these drugs penetrate to the CNS, and there are some side effects 
associated with butorphanol treatment, such as nausea, drowsiness, and abnormal dreams. 
Nalfurafine seems to be well tolerated (Stull et al., 2016) but the underlying mechanism as to 
why is unclear. There are ongoing clinical trials using peripherally-restricted KOR agonists CR-
845 and asimadoline to test their efficacy in treating pruritus (ClinicalTrials.gov, 2016b); 
(ClinicalTrials.gov, 2016a).  
Overall, there is substantial evidence from preclinical and clinical studies for kappa 
opioid regulation of pain and itch sensation via KORs in various regions of the nervous system, 
including the periphery. Although there is evidence for expression of KORs on primary afferent 
neurons, there is also some evidence for expression on other peripheral cell types (Cai et al., 
2016); (Wittert, Hope, & Pyle, 1996); (Gaveriaux, Peluso, Simonin, Laforet, & Kieffer, 1995). 
Therefore, the characterization of these neurons and other cell types and the effect that KOR 
activation has on their activity is importamt for determining the mechanisms underlying 
peripherally-restricted KOR agonist-induced analgesia and antipruritus. This knowledge can aid 
in the development of targeted treatments for specific pain and itch conditions. 
1.3 KOR EXPRESSION IN PRIMARY AFFERENTS 
As discussed above, preclinical and clinical studies have established a role for KORs in 
modulating nociception and pruritoception, even by KOR drugs that do not cross the BBB and 
are restricted to the periphery. For drugs targeting KORs to be used as effective therapies, it is 
important to characterize the primary afferents expressing KOR to best understand how this 
system modulates somatosensation as these neurons transmit somatosensory information to the 
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CNS. Previous work has established Opkr1 mRNA and KOR protein expression in primary 
afferents in the DRG. In-situ hybridization (ISH) studies investigating opioid receptor mRNA 
distribution in primary afferent populations in the DRG report that Oprk1 mRNA is 
predominantly found in small-to-medium diameter afferents (Mansour et al., 1994); (Mansour, 
Burke, Pavlic, Akil, & Watson, 1996); (M. K. Schafer, Bette, Romeo, Schwaeble, & Weihe, 
1994) which is consistent with expression on putative nociceptors, although there was mention of 
faint labeling in larger diameter neurons (Mansour et al., 1996) which are not necessarily 
nociceptive neurons. An immunohistochemical (IHC) study using a KOR antibody reported 
similar findings of KOR protein expression mainly in small diameter neurons; about 9% of the 
total number of DRG afferents in naïve rats were immunoreactive (IR) for the KOR (Ji et al., 
1995). To characterize these afferents in more detail a few colocalization studies have been 
performed. These studies have found overlap between Tac1 mRNA (encoding the neuropeptide 
substance P) and Oprk1 mRNA (Minami, Maekawa, Yabuuchi, & Satoh, 1995), and a study in 
acutely cultured rat DRG neurons observed KOR-immunoreactivity in afferent subtypes that also 
express the neuropeptides CGRP and/or substance P (Rau, Caudle, Cooper, & Johnson, 2005). 
These data suggest that KOR is expressed on at least of subgroup of peptidergic primary 
afferents, many of which are nociceptors and likely involved in neurogenic inflammation (Grant, 
Gerard, & Brain, 2002). Physiological recordings of DRG neurons in culture have shown that 
some afferents that respond to multiple opioid receptor agonists, but responsiveness to one 
opioid receptor does not necessarily mean an afferent responds to another or all agonists, 
suggesting that there are distinct subtypes of primary afferents expressing different opioid 
receptor types (Werz & Macdonald, 1984); (Macdonald & Werz, 1986); (Moises et al., 1994). 
Together, these studies consistently report KOR expression in small diameter, putative 
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nociceptive neurons which aligns with reports that KOR agonists, particularly peripherally-
restricted agonists, dampen nociceptive and pruritoceptive processing. Yet detailed 
characterization of the primary afferent subtypes expressing KOR, beyond overlap with other 
opioid receptor and neuropeptides, has not been reported. This information would increase our 
understanding of how KORs on primary afferent neurons act to modulate somatosensory 
information. 
1.3.1 Localization of KOR on central and peripheral terminals 
Primary afferent neurons are pseudo-unipolar neurons and have endings in both the CNS that 
terminate in the dorsal horn of the spinal cord and endings in the PNS that terminate in various 
peripheral tissues (Kandel, 2012). KORs can modulate transmission through primary afferent 
neurons via expression at either terminal. Although peripherally-restricted KOR agonists are a 
popular target in terms of drug development, untangling the effect of KOR activation on the 
circuitry in the spinal cord is important as well. If peripherally-restricted KOR agonists are not 
successful in clinical trials, an alternative method of targeting KOR for therapeutic use could be 
spinal delivery via an epidural injection. There is supportive evidence in the literature that kappa 
opioids play a role in modulating somatosensory circuitry in the dorsal horn (Randic, Cheng, & 
Kojic, 1995) (Kardon et al., 2014), but there are still some uncertainties remaining regarding 
KORs’ role on primary afferent terminals.  
Several groups have identified and investigated the function of dynorphin-expressing 
spinal dorsal horn interneurons and report findings consistent with these interneurons regulating 
itch sensation or mechanical pain after injury (Sardella et al., 2011); (Kardon et al., 2014); (Duan 
et al., 2014). These neurons consist predominantly of inhibitory, GABA and / or glycinergic 
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interneurons, but there is also a smaller population of excitatory, glutamatergic dynorphin-
expressing neurons (Sardella et al., 2011). There is a likelihood that, in addition to acting on 
KORs expressed on spinal neurons, dynorphin also acts on KORs expressed on the central 
terminals of primary afferents. MOR and DOR agonists have been shown to inhibit glutamate 
release from the central terminals of sensory afferents (Francois et al., 2017; Heinke, Gingl, & 
Sandkuhler, 2011; Kohno, Kumamoto, Higashi, Shimoji, & Yoshimura, 1999). There is some 
evidence that KOR agonists may likewise inhibit primary afferents in superficial lamina (Randic 
et al., 1995), but this effect has not been universally observed (Ikoma et al., 2007; Kohno et al., 
1999).  
KOR antibody staining has been observed in peripheral nerve fibers (Labuz et al., 2009) 
and accumulation of KOR protein at the proximal site of a ligated sciatic nerve has been inferred 
from increased intensity of KOR-IR in this area, suggesting that the KOR is trafficked to the 
periphery (Ji et al., 1995). This suggests that KOR protein is translated at the soma and 
transported to peripheral terminals. Several studies have reported results that support the 
presence of KOR on peripheral nerve terminals. For example, application of KOR agonists to a 
peripheral site of stimulation either decreases nerve activity or neuropeptide release (Averbeck, 
Reeh, & Michaelis, 2001); (Russell, Leslie, Su, Watkins, & Chang, 1987); (Andreev, Urban, & 
Dray, 1994). In summary, these data suggest that KOR protein is transported to the central and 
peripheral terminals and can play a functional role in modulating somatosensory transmission at 
each level.  
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1.4 GAP IN KNOWLEDGE 
Although preclinical studies using peripherally-restricted KOR agonists have shown reductions 
in pain- and itch-related behaviors, the move from animal models to clinical trials in humans is 
accompanied by many complexities that cannot be modeled in the lab. For clinical trials to be 
effective, a targeted approach based on a mechanistic understanding on the kappa opioid system 
may have the highest likelihood of succeeding. Therefore, understanding the primary afferent 
types that express the KOR and how activation of this receptor affects nociceptive and 
pruritoceptive processing is important if peripherally-restricted compounds are to be further 
developed and used successfully for the treatment of pain and itch conditions.  
An interest in defining distinct neuronal types has been a large driver of our 
understanding of how the nervous system is organized to process information since the early 
drawings of Ramon y Cajal at the turn of the 20th century. Neuronal anatomy is a critical aspect 
of cell type definition, as the structure of neuronal types and their connectivity to other regions 
give insight into their functional properties. More modern techniques have allowed for cell type 
definition through physiological properties, protein expression, and even wide-scale 
transcriptional profiling. The growing use of genetic mouse models has given neuroscientists the 
ability to visualize neuronal types of interest, to characterize their anatomical structure and 
connectivity to other neuronal types in order to inform circuit function. These models also allow 
for the expression of exogenous proteins in specific neuronal types, allowing researchers to 
manipulate their activity; such as the use of light-gated channels to excite or inhibit neuronal 
activity within a particular circuit and / or during a particular behavior (Deisseroth, 2015). This 
approach has led to advances in our understanding of the role of different neuronal cell types in 
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disorders such as schizophrenia (Cho & Sohal, 2014) and Parkinson’s disease (Vazey & Aston-
Jones, 2013). 
Primary sensory afferents in the DRG are no exception to the interest in the definition of 
neuronal cell types, which could inform not only how the nervous system processes different 
somatosensory stimuli, but also lead to insights for the treatment of disease. Traditionally, 
primary afferent neuron subgroups were differentiated based on the characteristics of soma size, 
conduction velocity, anatomy of their peripheral terminals, and the lamina they terminate in the 
dorsal horn (Le Pichon & Chesler, 2014); (Kandel, 2012). Four primary afferent fiber types – C, 
Aδ, Aβ, and proprioceptors – are each generally involved in different roles in somatosensory 
processing. However, there is a depth of diversity within primary afferents that is not fully 
captured by these classifications or the characteristics they are based on. Molecular genetic 
techniques have allowed for the further division of subgroups and the study of their function (Le 
Pichon & Chesler, 2014). Other groups have built upon this understanding by using single cell 
transcriptional profiling in an effort to identify functional groups based on unbiased classification 
schemes (Usoskin et al., 2015); (C. L. Li et al., 2016); (Chiu et al., 2014). However, the opioid 
receptors have not been robustly detected in these approaches and hence it is unclear which of 
these de novo subgroups of DRG neurons express the KOR, or if KOR-expressing afferents are a 
new subgroup of their own. Understanding which functional neuronal subtypes express KORs 
may lead to new advancements in the understanding of opioid regulation in primary afferents, 
and tools that allow for the identification and manipulation of this subgroup can advance our 
knowledge of their involvement in somatosensory processing. 
Given the strong evidence for regulation of nociception and pruritoception through kappa 
opioid signaling, the need for an alternative strategy to specifically harness the analgesic and/or 
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antipruritic properties of KOR agonists, evidence for the expression of KOR on primary afferent 
terminals in the periphery, and the ability of KORs to affect the processing of these cells, our 
goal was to better characterize the expression pattern of KOR in primary afferents and 
understand the role of KOR on in modulating primary afferent activity. The experiments herein 
aim to characterize the primary afferents subtypes expressing the KOR and to use this 
information to perform studies investigating the effect of KOR activation on somatosensory 





2.0  KOR IS EXPRESSED BY AT LEAST TWO DISTINCT GROUPS OF PRIMARY 
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As we are particularly interested in how the nervous system processes somatosensory 
information and in developing better treatments for pain and itch conditions, the first cell type(s) 
expressing KOR we wanted to characterize were primary sensory afferents in the DRG. Previous 
work has reported that KOR is expressed primarily in small-to-medium diameter neurons 
through characterization of the primary afferent types that express KOR in the DRG using either 
ISH or IHC (Ji et al., 1995); (Mansour et al., 1994); (Maekawa et al., 1994); (M. K. Schafer et 
al., 1994), but more extensive characterizations of the afferents expressing KOR have been 
limited to co-expression of one or two other proteins (Ji et al., 1995); (Minami et al., 1995); (Rau 
et al., 2005) or responsiveness to one other agonist (Werz, Grega, & MacDonald, 1987); (Moises 
et al., 1994).   
In somatosensory research, there has been a recent and growing interest in characterizing and 
defining subgroups of primary afferents within the DRG. Several recent papers have described 
analyses of transcripts on a single cell level, as unique transcript expression profiles may lead to 
novel definitions of cell types and may provide new insights into functional properties of sensory 
afferents (Usoskin et al., 2015; Li et al., 2016; Chiu et al., 2014). Yet, opioid receptor transcripts 
have not been robustly detected in analyses of single-cell RNA sequencing of sensory afferents 
(Usoskin et al., 2015); (C. L. Li et al., 2016); (Chiu et al., 2014). Thus, a reliable tool to identify 
KOR-expressing neurons is much needed to progress our understanding of the characteristics of 
these afferents, the role of KOR signaling in somatosensation, and how best to target this 
receptor for therapeutic use. Having a tool that can reliably identify cells that express the KOR 
would go a long way towards increasing our ability to study how kappa opioid signaling effects 
cellular processing (including somatosensation) and how drugs targeting this receptor could be 
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optimally designed and delivered to achieve a desired effect. Often, progress towards 
characterizing a cell type that expresses a particular protein is made by using an antibody that 
specifically recognizes the protein marker of interest. However, an antibody that produces 
reliable staining of the KOR has been notoriously difficult to find. 
Previously, Cai et al. (Cai et al., 2016) reported the generation of a KOR-cre knockin allele. 
When KOR-cre cells were visualized using a Rosalsl-tdt allele, cells throughout the nervous system 
were labeled, including primary afferent neurons in the DRG. Therefore, the experiments herein 
aimed to determine if the KOR-cre allele could be used to reliably identify primary afferents 
expressing KOR. If that was the case, this tool could be used to characterize the neurochemical, 
anatomical, and transcriptional aspects of KOR-expressing neurons. This information would then 
form the basis for the design of studies investigating the effects of KOR agonists on 
somatosensory processing. Based on the previous literature investigating the distribution of KOR 
in the DRG, their functional properties, and the effectiveness of KOR agonists in reducing 
various forms of nociception and pruritoception, it was predicted that KOR would be expressed 
primarily by small diameter, peptidergic, nociceptive / pruritoceptive neurons that target skin in 
addition to deeper tissues of the body. 
2.2 MATERIALS AND METHODS 
2.2.1 Animals 
Mice were given free access to food and water and housed under standard laboratory conditions. 
The use of animals was approved by the Institutional Animal Care and Use Committee of the 
 24 
University of Pittsburgh. KOR-cre knockin mice were generated by targeted Cre recombinase 
into the endogenous KOR locus (Oprk1) as previously described (Cai et al., 2016) and are 
maintained on a mixed C57bl/6.129J background.  For electrophysiology, 
immunohistochemistry, and single cell RT-PCR experiments, KOR-cre heterozygous mice were 
mated with Ai9 cre-responsive tdTomato reporter mice (Madisen et al., 2010) or with Ai32 cre-
responsive ChR2-eYFP reporter mice (Madisen et al., 2012)(The Jackson Laboratory). 
2.2.2 Electrophysiology 
Patch-clamp recordings in dissociated DRG neurons 
Mice (5-8 weeks old) were deeply anesthetized and transcardially perfused with ice-cold 
Ca2+/Mg2+-free HBSS (Invitrogen). Bilateral DRG (L2–L5) were dissected into cold HBSS and 
dissociated as described previously (S. A. Malin, Davis, & Molliver, 2007). Cells were plated in 
DMEM F-12 (Invitrogen) containing 10% fetal bovine serum (FBS) and antibiotics 
(penicillin/streptomycin, 50 U/ml). Two hours later, coverslips were flooded with Ca2+/Mg2+-
free HBSS (Invitrogen) containing 5 mM HEPES and stored at room temperature. Experiments 
were performed within 8 h of tissue harvest. 
Borosilicate glass electrodes were filled with (in mM) 100 Cs-methanesulfonate, 5 Na-
methanesulfonate, 40 TEA-Cl, 1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA, 2 Mg-ATP, and 1 Li-
GTP, pH 7.2 (adjusted with Tris-base), 310 mOsm (adjusted with sucrose). Neurons were 
continuously superfused with a bath solution that contained (in mM) 100 Choline-Cl, 30 TEA-
Cl, 2.5 CaCl2, 0.6 MgCl2, 10 HEPES, and 10 glucose, pH 7.4 (adjusted with Tris-base), 320 
mOsm (adjusted with sucrose). Currents were evoked up to three times from each neuron before, 
during, and after drug application with the following voltage-clamp protocol: 50ms, 70mV steps 
 25 
from a holding potential of −70mV to 0mV. Series resistance compensation (>70%) was used for 
all voltage-clamp recordings. To reduce the impact of leak currents, a p/4 leak subtraction 
protocol was used with a holding potential of −90 mV during the acquisition of the leak pulses. 
Response to drug application was defined as at least a 10% change from baseline.  
Extracellular single-fiber recordings 
Recordings were performed as previously described (McIlwrath, Lawson, Anderson, 
Albers, & Koerber, 2007). Briefly, Mice (4 - 6 weeks old) were deeply anesthetized, the 
hindlimb was shaved, and mice were perfused transcardially with oxygenated 6 °C sucrose-based 
artiﬁcial cerebral spinal ﬂuid (ACSF) in mM: 39.0 sucrose, 0.9 KCl, 1.2 KH2PO4, 1.3 MgSO4, 
2.4 CaCl2, 26.0 NaHCO3, 10.0 D-glucose. The saphenous nerve and its innervation ﬁeld were 
excised, transferred to a dual chamber recording dish, superfused with chilled oxygenated 
synthetic interstitial ﬂuid (SIF) in mm: 123.0 NaCl, 3.5 KCl, 0.7 MgSO4, 1.7 NaH2PO4, 2.0 
CaCl2, 9.5 sodium gluconate, 5.5 glucose, 7.5 sucrose, 10 HEPES, pH 7.4, and warmed slowly to 
31 °C. The skin was pinned epidermal-side up on a rigid perforated metal platform, and the level 
of the circulating SIF was adjusted to bathe the corium side from underneath. This allowed for 
mechanical and optical stimulation of the dry skin (adapted from (Koerber & Woodbury, 2002)). 
The saphenous nerve was threaded into a mineral oil-ﬁlled recording chamber and placed on top 
of a small mirror for dissection. The nerve was de-sheathed and extracellular recordings were 
obtained from functionally identiﬁed single myelinated ﬁbers in teased ﬁlaments draped over a 
silver hook electrode (Kress, Koltzenburg, Reeh, & Handwerker, 1992; Reeh, 1986). Signals 
were amplified, digitized, and recorded using Spike2 software for offline analysis. 
Once an individual fiber was isolated, its receptive ﬁeld (RF) was located using a small 
brush and tested for light responsiveness using a blue laser (473 nm). Conduction velocity was 
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assessed using a concentric electrode in the RF (distance to electrode/stimulus-response delay). 
Myelinated fibers were defined as conducting faster than 1 m/s (Koltzenburg, Stucky, & Lewin, 
1997). A feedback-controlled constant force stimulator (Dual Mode Lever System, Aurora 
Scientiﬁc, Aurora) with a 1-mm diameter contact area was used to determine mechanical 
threshold of the cell and to characterize its response to suprathreshold stimuli. Constant force 
stimuli consisting of square waves of 5 sec duration were applied in an ascending series of 1, 5, 
10, 25, 50, and 100 mN with 30-s interstimulus intervals.  
2.2.3 Intrathecal (IT) injections 
Intrathecal injections were performed as previously described (Kardon et al., 2014). Mice were 
anesthetized (2.0% for induction and 1.5% for maintenance) with isoflurane in a flow of O2, 
placed in a prone position on top of a heating pad covered with a blue fiber disposable towel, and 
the hair on their back was clipped. The caudal paralumbar region was securely held by the thumb 
and middle fingers of the left hand, and the index finger was placed on the tip of sixth lumbar 
(L6) spinous process, the highest point of the vertebral column. All intrathecal injections were 
delivered in a total volume of 5 μL using a 30-gauge needle attached to a luer-tip 25 μL 
Hamilton syringe. The needle was inserted into the tissue at a 45° angle and through the fifth 
intervertebral space (L5–L6) causing a sudden lateral movement of the tail. Solution was injected 
at a rate of 1 μL/s. The needle was held in position for 10 s and removed slowly to avoid any 
outflow of the solution. Anesthesia was discontinued and the mice recovered from anesthesia 
within 5 min. 
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2.2.4 Histology 
For immunostaining of tissue sections, 20μm thick sections were cut with a cryostat (Leica) and 
mounted onto Superfrost Plus slides (Fisher Scientific) and stored at -20°C until use. Tissue 
sections were blocked in 10% donkey serum and 0.25% Triton-X in PBS for 1 h at room 
temperature. Sections were incubated with primary antibodies in block overnight at 4-8°C. Slides 
were washed 4 x 5 min in PBS containing 0.1% triton-X. Primary antibodies were revealed with 
species-specific secondary antibodies raised in donkey and conjugated to Pacific Blue, 
Alexa488, Alexa555, or Alexa647 (Life Technologies) diluted at 1:500 in block, incubated for 1 
hour at RT, washed as above, and coverslipped. The primary antibodies used were: sheep anti-
CGRP (1:2000, Abcam, ab22560), rabbit anti-NF200 (1:1000, Sigma Aldrich, N4142), mouse 
anti-NF200 (1:500, Sigma Aldrich, N0142), rabbit anti-TH (1:1000, Millipore, AB152), mouse 
anti-parvalbumin (1:1000, Millipore, MAB1572), rabbit anti-PGP9.5 (1:1000, UltraClone 
Limited, RA95101), rabbit anti-substance P (1:10000, Immunostar, 20064), goat anti-TRPV1 
(1:1000, Santa Cruz Biotechnologies, sc-12489), rabbit anti-RFP (1:1000, Rockland, 600-401-
379S), and rabbit anti-TRPM8 (1:500, gift from M. Tominaga, Okazaki Institute for Integrative 
Bioscience). IB4 binding was visualized using biotinylated IB4 (Sigma, 1:500, L2140) and 
fluorophore-conjugated streptavidin (Life Technologies, 1:500) in place of primary and 
secondary antibodies.  
For wholemount immunostaining of hairy skin, the hair was shaved using clippers 
following perfusion, and back skin was dissected. Skin sections were post-fixed for 
approximately 30 minutes in 4% PFA then rinsed in 1X PBS. Underlying adipose tissue was 
dissected from the skin, and then tissue was cut into small pieces, approximately 1 cm x 0.5 cm. 
Tissue was rinsed 30 min x 5 – 8 hours at room temperature in PBS containing 0.3% triton-X, 
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with each vial containing one tissue square and at least 1mL volume. Tissue was incubated in 
primary antibodies (listed above) diluted in PBS containing 0.3% triton-X, 5% normal donkey 
serum, and 20% dimethylsulfoxide (DMSO) for 4 – 8 days at 4-8°C with agitation. Tissue was 
then washed as above. Primary antibodies were revealed with species-specific secondary 
antibodies raised in donkey and conjugated to Alexa488, Alexa555, or Alexa647 (Life 
Technologies) diluted at 1:500 in block, incubated for 2 – 4 days at RT with agitation. Tissue 
was washed as above, mounted on slides and coverslipped.  
Slides were imaged using a Nikon A1R confocal microscope through either a 20x or 60x 
oil-immersion lens. Full-tissue thickness z-stacks (0.5-1 μm sections) were taken. For 
quantification of co-localization of KOR-cre positive neurons, images were analyzed and 
neurons were counted using Nikon Elements Advanced Research Software. 
For quantification of co-localization of KOR-cre positive neurons, full-tissue thickness z-
stack images of lumbar (L1 - L6) DRGs were analyzed. At least seven individual sections DRG 
were analyzed per mouse for each marker analyzed, and at least 3 mice were analyzed per 
developmental time point. Sections of DRG analyzed were at least 100 μm apart in order to 
avoid counting a single neuron multiple times, and only neurons with visible nuclei were 
counted. Neurons were counted using Nikon Elements Advanced Research Software.  
2.2.5 Single-cell RT-PCR 
Backlabeling 
Mice were anesthetized with isoflurane (2%) and an incision was made on the medial surface of 
the right thigh, near the knee. The saphenous nerve was isolated with an effort to cause only a 
minimum amount of soft tissue damage and the nerve was insulated from the surrounding tissues 
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using parafilm. The chosen dye (1% Alexa 488-wheat germ agglutinin (WGA)), was injected 
into the nerve via a quartz pipette using a picospritzer (World Valve Corporation, Picospritzer 
II). The area was rinsed with saline, the parafilm was removed, and the wound was closed using 
silk sutures.  
Cell dissociation and pickup 
Mice (5-8 weeks old) were deeply anesthetized and transcardially perfused with ice-cold 
Ca2+/Mg2+-free HBSS (Invitrogen). Bilateral DRG (L2–L5) were dissected into cold HBSS and 
dissociated as previously described (Malin et al., 2007). Cells were plated onto laminin coated 
coverslips and then placed in culture conditions for 45 minutes to promote adhesion. Before 
pickup, cultures were flooded with cell collection buffer (in mM) 140 NaCl, 10 glucose, 10 
HEPES, 5 KCl, 2 CaCl2, 1 MgCl2). Fluorescent cells were picked up with borosilicate glass 
pipettes (World Precision Instruments) held by a 3-axis micromanipulator. After confirming 
pickup using fluorescence, pipette tips were broken off into tubes containing 3uL of lysis buffer 
(Epicentre, MessageBOOSTER kit), and stored at -80ᵒC until use. 
Single cell amplification and qPCR 
Transcripts from single cells were reverse transcribed and linearly preamplified using the 
MessageBOOSTER kit for cell lysate (Epicentre). After preamplification, the products were 
cleaned with RNA Cleaner & Concentrator-5 columns (Zymo Research) and transcript levels 
were quantified using qPCR with optimized primers and SsoAdvanced SYBR Green Master Mix 
(BioRad). Cycle-time (Ct) values were determined using regression. Quantification threshold 
was determined to be interreplicate average of 35 Ct, the point where replicates have a 95% 
chance of reoccurring, and the GAPDH threshold for cell inclusion was set to 25 Ct to ensure we 
could detect transcripts a thousand-times less prevalent than GAPDH. If a cell met the criteria for 
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inclusion, it would be corrected for primer efficiencies using the Pfaffl method (Pfaffl, Lange, 
Daxenberger, & Meyer, 2001). 
2.3 RESULTS 
2.3.1 KOR-cre knockin mouse as a tool to identify primary afferents expressing KOR 
In order to identify cells that express the KOR, a KOR-cre knockin allele was used where cre 
recombinase (cre) replaces the initial coding sequence of the Opkr1 gene (Cai et al., 2016). 
Crossing these mice to mice harboring an allele with a cre-dependent fluorescent reporter (the 
Rosalsl-tdtomato allele, known as Ai9; Jax labs) allows us to visualize KOR-cre Rosalsl-tdtomato 
primary afferents in the offspring. However, this approach results in tdtomato (tdt) expression in 
cells that have expressed KOR-cre during any point of development and therefore, tdt expression 
is not necessarily representative of neurons that express KOR protein in adulthood. So as to 
target the neurons expressing KOR-cre in the DRG during adulthood, we performed an 
intrathecal (IT) injection in adult KOR-cre mice (P39-P40) of cre-dependent virus 
AAV9.CAGGS.FLEX.ChR2-tdt.WPRE.SV40 (FLEX.ChR2-tdt; PennVector) (Vulchanova et 
al., 2010); (Dayton, Wang, & Klein, 2012). This approach is intended to target expression of the 
light-gated ion channel channelrhodopsin 2 (ChR2) fused to tdt, but only in neurons expressing 
cre, and therefore also highly likely expressing KOR, at the time of injection.  
First, in collaboration the Scherrer laboratory, dual fluorescent in-situ hybridization 
(FISH) was conducted to determine the overlap of Oprk1 mRNA and FLEX.ChR2-tdt expression 
(Figure 1A). The vast majority of the FLEX.ChR2-tdt positive neurons co-localized with Oprk1 
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expression (92.33% ± 3.70%; n=3 mice), and 93.62% ± 2.90% (n=3 mice) of the Oprk1 
expressing neurons were co-localized with FLEX.ChR2-tdt (Figure 1A-B). Second, in 
collaboration with the Koerber laboratory, to verify that the KOR-cre allele is specific to neurons 
that express KOR, single-cell RT-PCR on FLEX.ChR2-tdt positive neurons was performed. We 
found that 83% (10/12 cells) of these cells expressed detectable levels of Oprk1 mRNA (Figure 
1C). In comparison, we found that no tdt negative DRG neurons from KOR-cre Rosalsl-tdt mice 
expressed detectable levels of Oprk1 mRNA (0/24 cells; 8 shown for illustrative purposes) 
(Figure 1C). We chose tdt negative cells from KOR-cre Rosalsl-tdt mice to ensure that, in using the 
KOR-cre allele, we were not neglecting to analyze a major population of DRG neurons that 
actually do express KOR but fail to cause recombination via KOR-cre. Together, these results 
show that using viral techniques to infect primary afferent neurons in adult KOR-cre mice is 
sufficient to cause recombination in primary afferents that are highly likely to express KOR, as 
the majority express Oprk1 mRNA, and that this approach is specific as cells that do not show 
recombination with the KOR-cre allele do not express Oprk1 mRNA. 
Previous studies in dissociated DRG neurons have demonstrated that application of a 
KOR agonist can cause inhibition of voltage-gated calcium current (VGCC) in a subset of 
primary afferent neurons (Bean, 1989); (Macdonald & Werz, 1986); (Moises et al., 1994); (Su et 
al., 1998); (Wiley et al., 1997). Therefore, we performed whole-cell patch clamp recordings on 
acutely dissociated DRG neurons, and measured the effects of dynorphin on VGCC to determine 
if KOR-cre neurons express functional levels of KOR protein. When recording from tdt-positive 
cells that were genetically labeled by the KOR-cre allele, dynorphin (0.1 or 1 μM) caused a 
significant decrease in VGCC in 77% of KOR-cre neurons (17/22 cells) (Figures 1D, 1E, and 
2B). In many cells VGCC amplitude returned to baseline upon washout of dynorphin (Figure 
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2A). Dynorphin application was also associated with a significant increase in rise time (Figure 
2C), consistent with the possibility that the inhibition of peak inward current reflects a KOR-
induced rightward shift in the voltage-dependence of channel activation (Bean, 1989). Moreover, 
the effects were specific to KOR since the decrease in current caused by dynorphin was blocked 
by the KOR antagonist nor-BNI (Figures 1D, 1E and 2D). Primary afferents that were not 
genetically labeled by the KOR-cre allele showed neither a decrease in the magnitude of VGCC 
nor an increase in rise time upon application of dynorphin (Figures 1E, 2B and 2C). These 




Figure 1. KOR-cre as a tool for targeting KOR-expressing DRG neurons 
A. Dual FISH of Oprk1 (green) and tdTomato mRNA (red) shows high co-expression (merge) in DRG neurons. 
Lumbar DRG neurons were infected with the Cre-dependent virus (AAV.FLEX.ChR2-tdTomato) via IT injection at 
P40. Arrowheads indicate cells co-expressing Oprk1 and tdTomato mRNA. Scale bar = 25 μm. 
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B. Quantification of (A). Most tdTomato positive neurons (red) co-expressed Oprk1 mRNA, and most Oprk1 
postitive neurons (green) co-expressed tdTomato. n = 3 mice. Data are presented as mean ± SEM. 
C. Single-cell RT-PCR of lumbar DRG neurons. KOR-cre mice were infected with an AAV.FLEX.ChR2-tdTomato 
virus via IT injection at P40. The majority of KOR-cre; AAV.FLEX.ChR2-tdtomato positive neurons, (red dots) 
express detectable levels of Oprk1 mRNA (8 of 10), while none (0 of 22) of the KOR-cre negative neurons (black 
dots) express detectable levels of Oprk1 mRNA (only 8 cells are shown for clarity; ND, not detected). Data are 
presented as the -log2 ΔCT expression relative to GAPDH expression within the same cell such that bigger numbers 
represent higher mRNA expression. Dots represent data points from individual cells. 
D. Representative traces of voltage-gated calcium currents (VGCC) in a genetically-labeled cell from a KOR-cre; 
Rosa26lsl-tdTomato mouse at baseline (black traces, top and bottom), in the presence of dynorphin (1 μm, red; top 
trace), and in the presence of dynorphin (1 μm) + norBNI (1 μm, yellow; bottom trace). Neurons were held at -70 
mV and a 50 ms step to 0 mV was applied. 
E. Quantification of the percent change in current amplitude of KOR-cre negative neurons (gray; n = 5), 
KOR-cre positive neurons in the presence of dynorphin (1 μm; red; n = 6), or KOR-cre positive neurons in the 
presence of dynorphin (1 μm) + norBNI (1 μm; orange; n = 3). There was a significant decrease in current amplitude 




Figure 2. The inhibition of VGCC by dynorphin is blocked by the opioid receptor antagonist norBNI. 
A. Representative traces of VGCC in a KOR-cre-positive neuron at baseline (black), in the presence of dynorphin 
(1 μm; red), and after washout (blue). Neurons were held at -70 mV and a 50 ms step to 0 mV was applied. 
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B - C. Quantification of the percent change in current amplitude (B) or rise time (C) of either KOR-cre negative 
neurons (gray; n = 5 neurons), KOR-cre positive neurons in the presence of 0.1 μm dynorphin (pink; n = 7 
neurons), or of KOR-cre positive neurons in the presence of 1 μm dynorphin (red; n = 6 neurons). There was a 
significant decrease in current amplitude in the presence of either 0.1 or 1 μm dynorphin in KOR-cre positive 
neurons relative to baseline (*, paired t-test, p < 0.05). There was a significant increase in the rise time in the 
presence of 1 μm dynorphin in KOR-cre positive neurons relative to baseline (*, paired t-test, p < 0.05). Data are 
presented as mean ± SEM. 
D. Quantification of the percent change in current amplitude of either KOR-cre positive neurons in the presence of 
dynorphin (1 μm; red), in the presence of norBNI (1 μm; orange), or in the presence of dynorphin (1 μm) and 
norBNI (1 μm; light orange). n = 3 neurons. Only dynorphin alone caused a significant decrease in the current 
amplitude (*, paired t-test, p < 0.05). Data are presented as mean ± SEM. 
 
2.3.2 KOR is expressed in distinct neurochemical and anatomical subsets of primary 
afferents 
After validating that the KOR-cre allele did indeed cause recombination in neurons that express 
KOR, next we wanted to use neurochemical markers in order to gain a preliminary 
understanding of the primary afferent subtypes expressing KOR. When visualizing the 
recombination pattern in KOR-cre primary afferent neurons in the DRG, we noted that both large 
and small diameter cell bodies were labeled (Figure 5E-G). This suggested the possibility that 
multiple subtypes of primary afferent neurons express KOR. To begin characterizing KOR-cre 
neurons in more detail, molecular markers that are consistently expressed in putative functional 
groups of primary afferents were used in immunohistochemical (IHC) experiments similar to 
other reports in the field (McCoy, Taylor-Blake, & Zylka, 2012); (Han et al., 2013); (Bardoni et 
al., 2014). Calcitonin gene-related peptide (CGRP) was used as a marker for peptidergic neurons 
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(Basbaum, 2008; Basbaum, Bautista, Scherrer, & Julius, 2009), Neurofilament-200 (NF200) as a 
marker for myelinated A-δ and A-β fibers (Basbaum, 2008; Basbaum et al., 2009) (L. Li et al., 
2011), and tyrosine hydroxylase (TH) which has shown to be expressed by a subset of C-fibers 
that includes, but is not limited to, C-fiber low-threshold mechanoreceptors (LTMRs) (L. Li et 
al., 2011; Seal et al., 2009). Quadruple label IHC experiments revealed that the vast majority 
(~95%) of KOR-cre FLEX.ChR2-tdt primary afferents were labeled with at least one of these 
three markers (Figure 3D). Of these three markers, KOR-cre, FLEX.ChR2.tdt neurons co-
localized primarily with CGRP-IR (52%) (Figure 3A) or with neurons showing both CGRP-IR 
and NF200-IR (~12%). KOR-cre overlap with NF200-IR neurons was slightly smaller (~23%) 
(Figure 3B), as was overlap with TH-IR (~8%) (Figure 3E). Little or no overlap was observed of 
KOR-cre neurons with either TRPM8-immunoreactive (IR) or parvalbumin-IR neurons, 
suggesting that KOR-cre does not cause recombination in either cool-sensing neurons (McKemy, 
Neuhausser, & Julius, 2002; Peier et al., 2002) or in proprioceptors (de Nooij, Doobar, & Jessell, 
2013) (Figure 4). 
 36 
 
Figure 3. KOR-cre labels distinct neurochemical and anatomical subsets of primary afferents 
A – C. IHC of lumbar DRG neurons from KOR-cre mice labeled using a Cre-dependent virus (AAV.FLEX.ChR2-
tdTomato; IT in adult) and co-stained with antibodies to CGRP (A), NF200 (B), and TH (C). Scale bar = 10 μm.  
D. Pie chart representing co-localization of immunohistochemical markers with virally-labeled (AAV.FLEX.ChR2-
tdTomato, IT in adult) KOR-cre DRG neurons. 52% ± 5% of KOR-cre neurons co-localize with CGRP (red), 12% ± 
6% co-localize with both CGRP and NF200 (yellow), 23 ± 6. % co-localize with NF200 (green), and 8% ± 2% are 
TH (blue). Only 5% ± 5% of KOR-cre neurons did not co-localize with any of these three markers (gray; n = 3 
mice).  
E – F. Representative images of lumbar spinal cord section of a KOR-cre mouse following an injection of 
AAV.FLEX.ChR2-tdt into the left sciatic nerve at P40. KOR-cre + FLEX.ChR2-tdt primary afferent terminals can 
be seen ipsilateral to the injection in the dorsal horn (E) in both the deeper dorsal horn below the IB4 band (F) and in 




Figure 4. KOR-cre labeled afferents to not co-localize with parvalbumin or TRPM8. 
A - B. Representative images of lumbar DRG sections showing little to no overlap between KOR-cre; RosalslChR2-eYFP 
positive neurons and TRPM8-IR (A) or parvalbumin (PV-IR; B), indicating that KOR-cre neurons do not include 
putative cool-sensing neurons or putative proprioceptors, respectively. 
 
In a separate triple label IHC experiment, we observed some overlap between KOR-cre 
FLEX.ChR2-tdt neurons and isolectin-B4-IR (IB4) (~11%), a marker expressed largely by non-
peptidergic putative nociceptors (Figure 4). However, of those KOR-cre, FLEX.ChR2-tdt 
neurons that were IB4-IR, the overwhelming majority were also CGRP-IR with ~90% of the  
IB4-IR KOR-cre cells also showing IR for CGRP (Figure 5). These results indicate that this 
group of KOR-cre neurons are a specific population of peptidergic IB4-binding cells. These 
cells, described in Han et al. (Han et al., 2013), show large overlap with a population of primary 
afferents the authors suggest are specifically tuned for itch sensation. 
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Many genes show a developmental pattern of expression that is different than that 
observed in adulthood. As a result, Cre alleles often show altered patterns of reporter expression 
depending on the developmental timing of recombination. The use of viral recombination 
provided an opportunity to address whether recombination using the KOR-cre allele varies as a 
function of time in terms of the proportion of neurons in the DRG that show recombination. 
Further, in combination with the IHC markers described above, it provided an opportunity to 
address whether KOR-cre expression in particular primary afferent subtypes changes across time. 
Experiments were performed to compare the recombination pattern that is observed when a 
reporter is introduced at three different stages of development: embryonic (using the Ai9 Rosalsl-
tdt reporter allele), post-natal day 1 (using AAV viruses delivered IP) (Foust, Poirier, Pacak, 
Mandel, & Flotte, 2008), and adult (using AAV viruses delivered IT) (Vulchanova et al., 2010); 
(Dayton et al., 2012).  
In general, the distribution of subtypes within the KOR-cre population at any of these 
three times is largely similar. Co-staining with CGRP, NF200 and TH revealed a similar 
proportion of KOR-cre neurons at any time point analyzed showed colocalization with these 
three markers (Figures 5A and 5B). Co-staining with IB4 and CGRP revealed a larger proportion 
of IB4-IR only KOR-cre neurons labeled in embryonic and early post-natal development, which 
shifted towards a larger proportion of IB4-IR and CGRP-IR KOR-cre neurons in adult labeled 
neurons (Figure 5A and 5B). This likely indicates that a larger proportion of IB4-IR neurons 
expressed KOR early in development, but no longer express KOR in adulthood. However, KOR-
cre- neurons that were labeled when adult mice were infected with Cre-dependent viruses made 
up a smaller number of the total DRG population than that observed when the recombination 
occurred during embryonic or early postnatal development (see Figure 5 for further detail). This 
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analysis revealed that similar proportions of the total KOR-cre population co-stained with either 
CGRP, NF200, or TH across development, but that there was a change from IB4 only KOR-cre 
neurons in early development to IB4 and CGRP KOR-cre neurons in adulthood. Thus, while 
largely similar patterns of recombination are observed, introduction of Cre-dependent reporters 
into adult KOR-cre mice is more specific for neurons that express KOR in adulthood, whereas an 
embryonic reporter would be useful in an analysis of the developmental expression of KOR. 
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Figure 5. Comparison of KOR-cre mediated recombination at different times during development. 
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A. To determine whether KOR-cre mediated recombination varies across an animal lifespan, the recombination that 
was observed following the introduction of a Cre-dependent reporter at three different stages of development was 
compared. KOR-cre mice were either crossed with Ai9 mice (RosalslChR2-eYFP), or infected with Cre-dependent virus at 
either P1 or in adult mice. Sections from DRG were quadruple labeled with the reporter and antibodies against 
NF200, CGRP, and TH, and the percentage of genetically-labeled cells that co-localize with one or more of these 
three markers was quantified. Gray bars represent the KOR-cre positive population in KOR-cre RosalslChR2-eYFP mice, 
red bars represent the KOR-cre positive population in mice injected with FLEX.ChR2-tdT virus IP at P1, and blue 
bars represent the KOR-cre positive population in mice injected with FLEX.ChR2-tdT virus IT at P40. When 
infection occurs in adult, only 5% of labeled KOR-cre afferents do not co-localize with either CGRP, NF200 or TH 
(i.e., KOR-cre only). However, if the reporter is introduced during embryonic or early post-natal development, the 
fraction of KOR-cre only afferents is significantly increased (One-way ANOVA with Tukey’s multiple comparison’s 
test, *, p < 0.05, n = 3 mice). In a separate experiment, sections were co-stained with antibodies to CGRP and with 
IB4. For each condition, KOR-cre neurons that co-localized with both CGRP and IB4 were observed. However, when 
the reporter was introduced embryonically, KOR-cre neurons that co-localized with IB4 but not CGRP (i.e., IB4 only) 
were observed. In contrast, when the reporter was introduced later, a significant decrease in the proportion of KOR-
cre afferents that co-stain with IB4 only was observed (One-way ANOVA with Tukey’s multiple comparison’s test, 
*, p < 0.05, n = 3 mice). Together, these findings suggest that labeling with the KOR-cre allele becomes more 
restricted over the course of development. Data are presented at mean ± SEM. Similar results were seen whether Cre-
dependent viruses were introduced via intrathecal or intrasciatic injection in adult mice (n = 3 mice per viral delivery 
route, data not shown). 
B - D. Pie charts representing the proportion of KOR-cre neurons that co-localize with various neurochemical 
markers. Charts illustrate that the proportion of each group remains similar across KOR-cre RosalslChR2-eYFP mice, 
KOR-cre + FLEX.ChR2-tdT delivered IP at P1 mice, and KOR-cre + FLEX.ChR2-tdT delivered IT at P40 mice. 
E - G. Representative image of a lumbar DRG section showing co-localization of KOR-cre neurons with NF200, 
CGRP, TH, and IB4 in KOR-cre RosalslChR2-eYFP mice (E), KOR-cre + FLEX.ChR2-tdT delivered  IP at P1 mice (F), 
and KOR-cre + FLEX.ChR2-tdT delivered IT at P40 mice (G). Arrows indicate KOR-cre positive neurons that co-




The IHC experiments above suggest that the KOR-cre allele mediates recombination in 
two major populations of primary afferents (CGRP-IR afferents or NF200-IR afferents). 
Previous work in mice  has shown that many CGRP-IR putative nociceptive neurons have central 
terminals that target the superficial dorsal horn (lamina I) (McCoy et al., 2012) while many 
myelinated A-δ and A-β fibers, in particular cutaneous myelinated low-threshold 
mechanoreceptors (LTMRs), have central terminals that target the deeper dorsal horn (lamina 
III-V) (Abraira et al., 2017). Thus, IHC was used to selectively visualize the central terminals of 
KOR-cre-expressing primary afferents. In order to do so without also labeling KOR-cre spinal 
interneurons, Cre-dependent AAV viruses were either injected into the sciatic nerve of adult 
mice (Figures 3E, 3F and 3G), or delivered IP at P1 (Figures 6A and 6B).  Many KOR-cre 
afferents terminated in the superficial dorsal horn where they co-localized with CGRP. In 
addition, KOR-cre positive afferents terminated in laminae III-IV, the LTMR recipient zone 
(Abraira et al., 2017). Furthermore, at least some of these fibers appeared to send collaterals in 
the dorsal funiculus (Figure 6A), consistent with the possibility that KOR-cre afferents include 
LTMRs that target the dorsal column nuclei (Horch, Burgess, & Whitehorn, 1976).  
Taken together, the neurochemical and anatomical data support the idea that KOR is 
expressed by presumed nociceptive peptidergic afferents whose central terminals target lamina I, 




Figure 6. KOR-cre labeled afferents include putative LTMRs that target the dorsal columns. 
A - B. Representative image of KOR-cre primary afferent terminals in the lumbar spinal cord. KOR-cre neurons 
were infected via an IP injection of AAV.FLEX.ChR2-tdT at P1. Arrowhead indicates KOR-cre positive terminals 
in the deeper dorsal horn below the IB4 band (A) and in the superficial dorsal horn that overlap with the CGRP-IR 
band (B). Arrow indicates KOR-cre positive fibers that appear to ascend in the dorsal column pathway. A similar 
pattern was observed in n = 3 mice. 
2.3.3 KOR is expressed in circumferential and lanceolate low-threshold 
mechanoreceptors 
Given there has been no previous indication of a role for KOR signaling in low-threshold 
mechanosensation, it was somewhat surprising to find KOR-cre expression in myelinated, large 
diameter fibers as well as in KOR-cre central terminals in the deeper dorsal horn, consistent with 
the location of the LTMR recipient zone (Abraira et al., 2017). The possibility of a group of 
KOR-expressing LTMRs is further supported by the presence of KOR-cre fibers in the dorsal 
column pathway (Figure 6A arrow), as several LTMR subtypes have an axonal branch that 
ascends along this pathway to the gracile nuclei (Horch et al., 1976). 
To investigate the identity of these afferent fibers further, we visualized their peripheral 
endings using Cre-dependent expression of ChR2-tdTomato in adult mice. In the hairy skin of 
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the hind paw, we observed that KOR-cre labeled afferents formed lanceolate (Figure 7A) or 
circumferential (Figure 7B) endings around hair follicles. Many of these afferents co-expressed 
NF200, indicating that they are myelinated, but they did not express CGRP. These results 
indicate these afferents could be a subset of circumferential endings that respond to light stoking 
of the skin and not to hair deflection (Bai et al., 2015). In contrast, KOR-cre afferents targeting 
Merkel disks or Meissner corpuscles in glabrous skin were not observed. KOR-cre afferents with 
circumferential or lanceolate endings were also observed in the hairy back skin, where they 
targeted multiple hair follicle types (Figures 8A and 8B), suggesting that KOR is expressed by a 
subset of LTMRs that target hair follicles across the body.  
 
Figure 7. KOR-cre mediates recombination of lanceolate afferents and circumferential field receptors 
A - B. IHC illustrating examples of a KOR-cre-labeled lanceolate fiber (A) or circumferential fiber (B) innervating 
hair follicles in the hind paw skin (red) and co-localize with NF200 (green). KOR-cre afferents were labeled with a 
Cre-dependent virus (AAV.FLEX.ChR2-tdTomato; IT in adult). Data are representative of n = 2 mice. Scale bar = 
10 μm. 
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C - D. Single fiber recordings were performed in KOR-cre, ROSAlslChR2-eYFP mice and fibers were identified with 
optogenetic tagging by their response to blue light stimulation of their cutaneous receptive field. A representative 
trace of a single fiber recordings from a KOR-cre-positive rapidly adapting A-fiber (C) and large dynamic range 
fiber (D) upon application of a mechanical stimulator the receptive field in the skin (5 sec, 10 mN) Data are 
representative of n = 4 cells of each type. 
 
 
Figure 8. KOR-cre labeled afferents form circumferential and lanceolate endings that target multiple hair 
types 
A - B. Wholemount IHC of the thoracic skin from a KOR-cre RosalslChR2-eYFP mouse co-stained showing KOR-cre 
positive lanceolate (left), and lanceolate and circumferential endings (right) innervating hair follicles in the back 
skin of a guard hair (A) and zigzag and/or awl/auchene hairs (B).  
 
To characterize the physiology of low-threshold KOR-cre afferents, we collaborated with 
the Koerber laboratory to use the ex vivo skin-nerve preparation and teased fiber recordings 
(McIlwrath et al., 2007). ChR2-expressing KOR-cre afferents were identified through their 
response to optogenetic stimulation (Figures 9A and 9B), and then characterized by their 
responses to the application of a range of constant mechanical forces (1 – 100 mN). Using this 
approach, afferents with two firing characteristics were observed. The first responded to low-
threshold stimulation (e.g., 5 or 10 mN), and consistently fired only once (at stimulus onset) or 
twice (at stimulus onset and offset) in response to mechanical stimulation throughout the range 
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of forces tested (Figures 7C, 9C and 9E). This electrophysiological signature is consistent with 
the possibility that KOR-cre afferents include rapidly adapting lanceolate fibers (Koerber & 
Woodbury, 2002); (L. Li et al., 2011). The second group also responded to low-threshold 
stimulation (Figures 7D, 9D and 9E). However, these afferents fired throughout the period of 
mechanical stimulation. Moreover, they showed dramatically increased firing rates in response to 
increasing forces, firing as many as 300 action potentials over 5 s (Figures 9E). These 
characteristics (low-threshold but responsive across a large dynamic range) are consistent with 
the idea that these fibers are afferents that form circumferential endings around hair follicles (Bai 
et al., 2015). Thus, these observations support the idea that KOR is expressed by two sensory 
neuron subtypes that target hair follicles. 
 
 
Figure 9. Electrophysiological characteristics of myelinated KOR-cre afferents 
Teased-fiber recordings were performed in a skin-nerve preparation of the dorsal hindpaw from KOR-cre; 
RosalslChR2-eYFP mice.  
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A - B. Optogenetic tagging was performed to identify KOR-cre afferents. Example traces of responses to blue 
light stimulation (470 nm, 20 ms) of the receptive field of afferents that were subsequently characterized as 
rapidly adapting (RA, A) or as large dynamic range (LDR; B).  
C - D. Graph of the number of spikes observed following mechanical stimulation of the receptive field with a 
piezo-electric stimulator at varying forces. Each shade represents an individual cell’s response across stimulus 
intensities. Rapidly adapting afferents fired only 1 or 2 spikes, irrespective of the force (C); large dynamic range 
fibers showed an increase in the spike number as a function of force. 
E. Table displaying the measured conduction velocity (CV), mechanical threshold, and the number of spikes 
following a given stimulus for each KOR-cre neuron recorded. 
 
2.3.4 KOR is expressed in a transcriptionally distinct subset of peptidergic afferents that 
target multiple tissue types 
The majority of sensory neurons targeted by the KOR-cre allele were not LTMRs, but rather 
peptidergic afferents, which are known to target cutaneous tissue but other peripheral tissues as 
well. As previous work from our laboratory and others have shown involvement of the kappa 
opioid system in regulating pruritoception (in addition to a role in nociceptive processing), and 
itch sensation arises in the skin, the skin from KOR-cre Rosalsl-tdt mice was co-stained with 
PGP9.5 (a marker for primary afferent neurons). KOR-cre afferents co-localized with PGP9.5 
and formed free nerve endings (Figure 12A) that traveled through the dermis into the epidermal 
layer of both the hairy and glabrous hind paw skin (Figure 11). However, they were not specific 
to the skin, since we observed labeled afferents in every nerve examined, including saphenous 
nerve, femoral nerve, sciatic nerve, L6 nerve, and the infraorbital nerve (Figures 10A - 10E). 
Further, KOR-cre FLEX.ChR2-tdt (IT injection) positive fibers were present in both the 
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saphenous and femoral nerves which innervate selectively cutaneous and muscular tissue of the 
hindlimb, respectively, indicating that it is highly likely primary afferents expressing KOR in 
adulthood target at least the skin and muscle (Figure 10F - 10G). Free nerve endings were also 
observed in visceral tissue, such as the lamina propria and muscularis layers of the bladder wall 
(Figure 10H). These findings indicate that KOR-expressing afferents likely innervate multiple 
tissue types throughout the body, and are therefore not limited to a specific peripheral target and 





Figure 10. KOR-cre afferents target tissues throughout the body 
A – E. Representative images of IHC from KOR-cre RosalslChR2-eYFP mice showing KOR-cre positive fibers that co-
localize with PGP9.5-IR in the femoral motor nerve, (A) saphenous nerve (B), sciatic nerve (C), L6 nerve (D) and 
the infraorbital nerve (E). These data suggest that KOR-expressing neurons innervate multiple tissue types 
throughout the body.  
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F – G. Representative images of IHC from KOR-cre + FLEX.ChR2-tdt delivered IT at P40 mice in the femoral 
motor nerve (F) and the saphenous nerve (G) that is consistent with the pattern observed in KOR-cre; RosalslChR2-eYFP 
mice. 
H. Representative images of IHC from KOR-cre RosalslChR2-eYFP mice showing KOR-cre positive fibers that co-




Figure 11. KOR-cre afferents form free nerve endings in the hairy and glabrous skin of the hind paw 
Representative images of IHC from KOR-cre RosalslChR2-eYFP mice showing KOR-cre positive fibers that co-localize 
with PGP9.5-IR in the hairy skin of the hind paw (top) and the glabrous skin of the hind paw (bottom). Scale bar = 
10µm. 
 
Consistent with previous literature that strongly suggests a role for KOR in peripheral 
modulation of nociception (for review, see (Vadivelu, Mitra, & Hines, 2011); (Vanderah, 2010)), 
KOR-cre expression is observed in putative peptidergic nociceptive (CGRP-IR) primary 
afferents (Figure 12B and 12C). Additionally, a high overlap with KOR-cre, FLEX.ChR2-tdt 
expression with other markers of putative peptidergic nociceptors was noted, such as substance P 
(~51%) (Figure 12B and 12C) and cation channel TRPV1 (~53%) (Figure 12B and 12C). While 
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many KOR-cre neurons expressed these classic ‘peptidergic’ markers many (Figure 12B arrows), 
but not all (Figure 12B arrowheads), of the peptidergic neurons co-localized with KOR-cre. Even 
when using a Cre-dependent tdTomato allele as a reporter to mark all cells that have ever 
expressed KOR at any time during development, only half of CGRP-expressing afferents were 
labeled (Figure 5E). This observation raises the question of whether or not the peptidergic 
neurons expressing KOR are a unique subset of this peptidergic population. 
To investigate the features that distinguished peptidergic Oprk1-positive neurons from 
peptidergic Oprk1-negative neurons, we turned to single cell quantitative RT-PCR. To enable 
characterization of CGRP-expressing subtypes, analysis was restricted to afferents that expressed 
Calcα (which encodes CGRP). First, we compared 15 KOR-cre positive afferents, in which the 
presence of Oprk1 message was subsequently confirmed, to 20 KOR-cre negative neurons with 
single cell RT-PCR (Figure 12D). This analysis revealed a number of peptidergic markers that 
were expressed at significantly higher levels in peptidergic afferents that express Oprk1 relative 
to peptidergic afferents that do not (Figures 12E – 12J). Oprk1-expressing afferents showed ~12-
fold higher Calcα and ~6-fold higher Tac1 expression on average, genes that encode for the 
neuropeptides CGRP and Substance P. Oprk1-expressing afferents also showed increased 
expression of transcripts encoding for several receptors; an ~4-fold increase in Trpv1, ~18-fold 
increase in Gfrα3, ~3-fold increase in TrkA, and ~3-fold increase in Ptgir. These findings suggest 
that, within the peptidergic class of primary afferents, KOR is preferentially expressed in a 





Figure 12. KOR is expressed by a transcriptionally distinct subset of peptidergic DRG neurons 
A. Wholemount IHC of the thoracic skin from a KOR-cre; RosalslChR2-eYFP mouse showing that KOR-cre-positive 
afferents (green) make up a subset of free nerve endings that terminate in the epidermis, as assessed by co-
localization with PGP9.5 (red). Scale bar = 10 μm. 
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B. IHC of DRG showing KOR-cre-labeled neurons co-localize with markers of peptidergic neurons. KOR-cre 
afferents were labeled with a Cre-dependent virus (AAV.FLEX.ChR2-tdTomato; IT in adult) Arrows indicate co-
localization; arrowheads indicate CGRP-, Substance P-, or TRPV1-expressing neurons that are not KOR-cre 
positive. Scale bar = 10 μm. 
C. Quantification of (B) showing the percentage of KOR-cre + FLEX.ChR2-tdT cells that co-localize with 
peptidergic markers. Data are presented as mean ± SEM (n = 3 mice). 
D. Schematic of single-cell RT-PCR experimental design. Lumbar DRG neurons from KOR-cre; RosalslChR2-eYFP 
mice were collected individually. Only peptidergic cells that expressed Calcα were analyzed. Transcript levels were 
compared between KOR-cre-labeled neurons that showed clear Oprk1 expression and KOR-cre negative neurons.  
E - J. Expression levels of Calc  (E), Tac1 (F), Trpv1 (G) TrkA, (H), Gfr 3 (I) and Ptgir (J) mRNA relative to 
GAPDH in KOR-cre negative (grey) and KOR-cre positive (orange) DRG neurons. Data are presented as the -log2 
ΔCT expression relative to GAPDH expression within the same cell such that bigger numbers represent higher 
mRNA expression. There was a significantly higher relative expression level of each transcript in KOR-cre positive 
neurons compared to KOR-cre negative neurons (Student’s t-test, p < 0.05). Inset shows fold-increase in the average 
expression level normalized to the average expression in KOR-cre negative neurons. Black bars represent mean ± 
SEM and colored dots represent data pionts from individual cells (n = 20 KOR-cre negative neurons, n = 15 KOR-
cre positive neurons). 
 
The transcriptional profile of KOR afferents could provide additional information for a 
potential functional role for these neurons. However, this would be further informed by 
understanding the peripheral innervation target and how that relates to the transcriptional profile. 
While the experiments above show that KOR-cre fibers innervate multiple tissue types, and that 
some transcripts are highly expressed in KOR-expressing afferents, it is not known whether the 
transcriptional profile is similar across KOR-expressing afferents that target different tissues. 
This information could provide insight into whether KOR-expressing afferents play a similar role 
in somatosensory processing across the body, and would provide insight into the effects of KOR 
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agonist on modulating somatosensation in different pathological conditions. In order investigate 
this further, the transcriptional profile of Rosalsl-tdt positive or Rosalsl-tdt negative neurons from 
KOR-cre mice backlabeled from either the saphenous or femoral nerve were analyzed. 
Fluorescent WGA was used as a backlabeling agent as it is preferentially transported by 
peptidergic afferents and therefore increased the likelihood of labeling this type of afferent for 
the analysis. When comparing all afferents backlabeled from the saphenous nerve to all afferents 
backlabeled from the femoral nerve (regardless of KOR-cre expression), there was generally 
higher expression of Calcα and Ptgir in femoral cells than in saphenous cells (Figure 13), 
consistent with the concept that afferent targeting different tissue types are unique in their 
properties. Consistent with the previous experiment (Figure 12 E-J), there was a greater 
proportion of KOR-cre Rosalsl-tdt positive neurons expressing high levels of Calcα, Tac1, Trpv1, 
Trka, Gfrα3, and Ptgir (Figure 13) compared to KOR-cre Rosalsl-tdt negative neurons backlabeled 
from either the saphenous nerve or femoral nerve (Figure 13). This qualitative assessment 
supports the conclusion that KOR-cre positive neurons express higher levels of particular 




Figure 13. KOR-cre afferents targeting muscular or cutaneous tissue express similar transcriptional profiles 
Table comparing transcript levels of KOR-cre Rosalsltdt negative (-) or KOR-cre Rosalsltdt positive (+) afferents 
backlabeled from either the saphenous (Saph) or femoral (Fem) nerves using WGA-488. Afferents were included in 
the table based on expression of Calcα in order to compare the KOR-cre Rosalsltdt negative (-) or KOR-cre Rosalsltdt 
positive (+) afferents within the peptidergic afferent population. Each cell in the table represents the ΔCT (Log2 
Transcript/GAPDH) for the given transcript in an individual afferent. The heat map is representative of relative 
expression within a transcript column across tissue target such that the lowest ΔCT value for Calcα (regardless of 
backlabel) is blue and the highest is red.  
Saph (-) = Saphenous backlabeled, KOR-cre Rosalsltdt negative; n= 7;  
Saph (+) = Saphenous backlabeled, KOR-cre Rosalsltdt postitive; n=9;  
Fem (-) = Femoral backlabeled, KOR-cre Rosalsltdt negative; n= 7;  
Fem (+) = Femoral backlabeled, KOR-cre Rosalsltdt postitive; n=9;  
n.d. = not detected. 
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2.4 DISCUSSION 
In this chapter, we have provided evidence that supports the use of KOR-cre allele to identify, 
target, and characterize primary afferents that express KOR in adult mice. When used in 
combination with a cre-dependent virus that leads to fluorescent reporter expression in adult 
KOR-cre primary afferents, experiments showed that the majority of the cells labeled using this 
approach express Oprk1 mRNA, and those that are not labeled do not express Oprk1, via single-
cell RT-PCR or dual FISH. Whole-cell patch clamp recordings from acutely dissociated DRG 
neurons demonstrated that KOR-cre neurons also express functional KOR, as dynorphin 
decreased the magnitude of VGCC in many KOR-cre neurons, but not in KOR-cre negative 
neurons. These experiments suggest that KOR-cre primary afferents are highly likely to express 
KOR, and that this approach does not exclude a large population of KOR-expressing neurons. 
Therefore, the KOR-cre allele was used as a tool to identify and characterize KOR-expressing 
primary afferent neurons. Through a combination of immunohistochemistry and single cell RT-
PCR, at least two distinct subtypes of KOR-expressing primary afferent neurons were identified. 
One is a group of transcriptionally distinct peptidergic afferents that centrally target the 
superficial dorsal horn and peripherally target multiple tissues including skin, muscle, and 
viscera. The other is a group of LTMRs that centrally target the deeper dorsal horn and dorsal 
column, and peripherally form circumferential and lanceolate endings around hair follicles in the 
skin. 
One of the most surprising findings was KOR expression in a subgroup of LTMRs. To 
the best of our knowledge, KOR expression in LTMRs has not been described previously. The 
past work investigating KOR mRNA or protein expression in the DRG has described the 
localization to primarily be in small-to-medium diameter neurons. As most LTMRs have 
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medium-to-large diameter somas (Le Pichon & Chesler, 2014), this finding was unexpected. The 
previous data aren’t necessarily inconsistent with the results from the experiments above, though, 
as several reports state that most of the KOR primary afferents were small diameter, but not all 
of the afferents were small diameter (Ji et al., 1995); (M. K. Schafer et al., 1994); (Mansour et 
al., 1996). Further, the large-diameter somata in the DRG that were KOR-cre positive were 
relatively low in number. The total number of KOR-cre neurons labeled in adulthood were a 
qualitatively low percentage of the total number of neurons (personal observation) which is 
consistent with a previous report from Ji et al. (Ji et al., 1995) that reports approximately 9% of 
DRG neurons expressed KOR-IR. Hence a small proportion of an already small group of 
afferents is not likely to warrant abundant description.  
While previous descriptions of KOR on LTMRs is lacking, work from the laboratory of 
Gregory Scherrer has suggested that the DOR is expressed by a subgroup of LTMRs, namely 
NF200-IR circumferential fibers in the hairy skin and fibers innervating Meissner’s corpuscles in 
the glabrous skin (Bardoni et al., 2014). However, the report from this group is controversial as 
they use a DOR-eGFP knockin mouse and there is debate as to whether addition of the eGFP 
sequence to the DOR protein alters expression pattern in terms of localization both within the 
cell and across cell types (H. B. Wang, Guan, Bao, & Zhang, 2008). As the main experiment 
identifying LTMRs as expressing DOR used this mouse line, further evidence may be needed to 
definitively determine if DORs modulate low-threshold mechanosensation. The studies 
investigating the expression of opioid receptors on LTMRs have drawn attention to the 
possibility that the opioid receptor system may play a more nuanced role in modulating 
somatosensation than the previous focus on the regulation of pain and itch. Interestingly, a few 
patients in clinical trials with the peripheral KOR agonist CR845 report paresthesia as a side 
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effect of the drug (personal communication). Although there are many possible underlying 
causes, it is tempting to speculate that this may be a result of the activation of KORs that are 
expressed by LTMRs.   
In addition to a subtype of LTMRs, KOR-expressing afferents also included a subset of 
peptidergic neurons that likely play a role in the transmission of pruritoceptive information from 
the skin and nociceptive information from tissues across the body. Gebhart and colleagues have 
previously investigated the effects of different classes of opioid receptor agonists on the primary 
afferents innervating the colon or the bladder and reported that a KOR agonist, but not MOR or 
DOR agonists, decreased responses of afferent fibers to distention (Sengupta, Su, & Gebhart, 
1996); (Su, Sengupta, & Gebhart, 1997a, 1997b). This suggested the possibility of differential 
tissue-type distribution of opioid receptor classes; KOR could be more highly expressed in the 
viscera than the other opioid receptor classes. Consistent with this hypothesis is the observed 
efficacy of KOR agonists in reducing behavioral responses in pre-clinical models of visceral pain 
(for review, see (Riviere, 2004); (Davis, 2012)) and in clinical trials in patients with irritable 
bowel syndrome (Mangel & Hicks, 2012); (Fant et al., 2017). However, the Gebhart lab 
discovered that the effects they observed in visceral afferents were due, at least in part, to 
arylacetamide KOR agonists’ effects on voltage-gated sodium channels (Su et al., 2009; Su, 
Joshi, Kardos, & Gebhart, 2002); (Joshi, Lamb, Bielefeldt, & Gebhart, 2003). This doesn’t 
necessarily rule out KOR expression in visceral afferents, but it does call into question a possible 
target tissue specificity. In the experiments described above, we observed KOR-cre labeled 
primary afferent nerve fibers in every nerve examined, supporting the idea that KOR-expressing 
fibers target multiple tissue types including cutaneous, muscular and visceral tissues. 
Quantifying the innervation density of KOR-expressing fibers in each type of target tissue would 
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be an interesting way to explore any possible target tissue preference for KOR-expressing 
afferents, and could provide further clues as to the role KORs play in modulating somatosensory 
information from across the body. Yet this type of experiment is difficult to perform given the 
current tools available; the KOR-cre Rosalsltdt mouse line labels some afferents that no longer 
express the KOR in adulthood, and using the viral approach to label KOR-cre expressing 
afferents in the adult requires either an intrathecal or intraneural injection which is never 100% 
efficient. Thus, both approaches are not suited to answer this type of question.  
Although we were not able to use the KOR-cre allele to quantify the innervation density in 
different target tissues, we did find that both saphenous and femoral backlabeled KOR-cre 
afferents expressed relatively high levels of a particular set of transcripts when compared to other 
peptidergic afferents. Oprk1-expressing peptidergic afferents expressed significantly higher 
levels of the transcripts Calcα, Tac1, Trpv1, Trka, Gfrα3, and Ptgir than the non-Oprk1 
peptidergic neurons, indicating that KOR-expressing afferents are a distinct subset of peptidergic 
afferents. Interestingly, several of these transcripts encode proteins that have been previously 
shown to be involved in mechanical and / or thermal hyperalgesia. Intraplantar injection of nerve 
growth factor (NGF), a ligand of TrkA, causes an increase in mechanical and thermal sensitivity, 
which can be partially blocked by a TRPV1 antagonist (Mills et al., 2013). A study from 
Moriyama et al. (Moriyama et al., 2005) suggests that PGI2 receptors (encoded by Ptgir) on 
primary afferents contribute to nociception, as PGI2 pretreatment has been shown to potentiate 
capsaicin-evoked inward currents and decrease the temperature threshold for TRPV1 activation 
in dissociated mouse DRG neurons (Moriyama et al., 2005). Consistently, this study showed that 
an intraplantar injection of PGI2 caused thermal hyperalgesia in the Hargreaves’ test. Further, 
prostacyclin administration in cultured rat primary afferents amplified release of CGRP and SP 
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(Hingtgen & Vasko, 1994). Many studies have shown that the peptides CGRP and SP play a 
large role in neurogenic inflammation. Neurogenic inflammation is inflammation resulting from 
activation of peripheral nerve fibers which causes release of the neuropeptides CGRP and SP, 
which subsequently cause plasma leakage and vasodiliation (Baluk, 1997). This type of 
inflammation induces hypersensitivity in addition to swelling and redness (for review, see 
(Richardson & Vasko, 2002)). Therefore, it is likely that most KOR-expressing peptidergic 
afferents are a subset of nociceptors activated by a particular set of chemical mediators and likely 
to be sensitized (or play a role in the sensitization of other afferents) following an injury or in an 
inflammatory state.  
In addition to the possible role in nociceptive processing and sensitization, KOR-cre 
afferents also showed IR that suggests KOR could be expressed by at least some primary 
afferents involved in pruritoception, which would be consistent with previous literature showing 
that peripherally-restricted KOR agonists inhibit scratching (Inan & Cowan, 2004); (Cowan et 
al., 2015). In terms of IHC staining, CGRP and IB4 are commonly used markers to distinguish 
between ‘peptidergic’ and ‘non-peptidergic’ afferents. When speaking in broad generalizations, 
peptidergic neurons are thought to be involved in the transmission of noxious thermal and 
chemical information, while non-peptidergic neurons are thought to be involved in the 
transmission of noxious mechanical information. These two groups are therefore generally 
referred to as non-overlapping, functionally distinct populations. While most CGRP-IR and IB4-
IR do not colocalize, a report by Han et al. (Han et al., 2013) described a small population of 
primary afferents that show colocalization with both markers. This study was characterizing 
primary afferents that express the Mas-related G-protein receptor A3 (MrgprA3), and 
approximately 65% of MrgprA3-cre neurons colocalized with both CGRP and IB4. Interestingly, 
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a ligand for this receptor is the anti-malarial drug and widely-used pruritogen, chloroquine. This 
group conducted further experiments whose results suggest that MrgprA3-expressing neurons are 
specifically tuned to transmit pruritoceptive information. As the small group of IB4-IR KOR-cre 
neurons in adulthood were also predominantly CGRP-IR, it is interesting to consider the 
possibility that some of the MrgprA3 afferents may express KOR which would be consistent 
with the idea that kappa opioids modulate itch sensation at the periphery as well as at the level of 
the spinal cord (Kardon et al., 2014). However, MrgprA3 mRNA was not highly detected in 
Oprk1 expressing afferents in the single-cell RT-PCR experiments. Due to the low number of 
Oprk1 expressing primary afferent neurons that were analyzed, though, it is difficult to draw any 
definitive conclusions. The evidence suggests the possibility that KOR is expressed on a subset 
of MrgprA3 afferents, but more experiments would be needed to test this prediction. Further, 
MrgprA3 afferents are only one subgroup of primary afferent fibers that have been proposed to 
be involved in detecting pruritoceptive stimuli (Mishra & Hoon, 2013); (Sun et al., 2009); 
(Usoskin et al., 2015); (Azimi et al., 2017) and future experiments could further delineate the 
expression of KOR on various itch subgroups and the role peripheral KOR agonists play in 
modulating itch sensation that arises from specific pruritogens.  
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3.0  THE EFFECT OF KOR AGONISTS CENTRALLY AND PERIPHERALLY 
The work described within this chapter is part of a manuscript that is under review at the journal 
Neuron. The draft of manuscript was prepared by myself and Dr. Sarah Ross, with review and 
editing by Drs. Rick Koerber and Michael Gold. Junichi Hachisuka, Yu Omori and myself 
designed, conducted, and analyzed the data from the recordings of spinal neurons in lamina I. Yu 
Omori developed the modified whole spinal cord preparation, conducted and analyzed the data 
from the recordings of spinal neurons in lamina III. All behavioral experiments were conducted 
by myself and Stephanie Fulton, with the exception of the Hargreaves’ test in KOR mutant and 
wild-type mice which was conducted by Huizhen Huang. Figures were prepared by myself and 
edited by Dr. Sarah Ross. 
3.1 INTRODUCTION 
Primary sensory afferents are pseudo-unipolar neurons with a single axon leaving the cell body, 
which then bifurcates; sending one branch to the dorsal horn of the spinal cord and the other 
branch to innervate a target tissue in the periphery. Previous studies have shown evidence that 
KORs in primary afferents are expressed on central and peripheral terminals and affect 
somatosensory transmission at either or both locations (Ji et al., 1995); (Labuz et al., 2009); 
(Stevens & Seybold, 1995); (Besse, Lombard, Zajac, Roques, & Besson, 1990a, 1990b). 
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Understanding the types of primary afferents that express KOR provides an opportunity to 
investigate the effect of KOR signaling on somatosensory transmission with more granularity.  
Several studies performed previously in the substantia gelatinosa of the rat spinal cord 
have investigated whether presynaptic KORs on central primary afferent terminals could 
decrease neurotransmitter release onto spinal cord neurons (Ikoma, Kohno, & Baba, 2007); 
(Kohno et al., 1999); (Randic et al., 1995); (Ueda et al., 1995). However, the results of these 
studies provide evidence that is both consistent and inconsistent with this possibility. Randic et 
al. (Randic et al., 1995) found that most of the modulation of dorsal horn neurons was due to 
KOR agonists’ action on post-synaptic receptors, but did observe evidence for presynaptic 
modulation in a smaller population of dorsal horn neurons. Experiments performed by Kohno et 
al. (Kohno et al., 1999) and Ikoma et al. (Ikoma et al., 2007) detected presynaptic inhibition of 
Aδ and C fiber-evoked EPSCs using either MOR or DOR agonists, but not a KOR agonist. Ueda 
et al. (1995) showed similar results, such that MOR and DOR agonists reduced capsaicin-
induced glutamate release in the dorsal horn, but KOR agonists did not. Further, several studies 
measuring neuropeptide release report no effect of KOR agonists on either SP (Zachariou 
(Zachariou & Goldstein, 1996); (Hirota et al., 1985) or CGRP (Collin et al., 1993); (Ballet et al., 
1998) levels in the dorsal horn following primary afferent stimulation. 
Anatomical and histological studies, however, support the presence of KORs on pre-
synaptic primary afferent terminals in the dorsal horn (Harris, Chang, & Drake, 2004); (Stevens 
& Seybold, 1995); (Ninkovic, Hunt, & Kelly, 1981); (Besse et al., 1990a, 1990b), so it is 
surprising that several studies report no effect of KOR agonists on neurotransmitter or 
neuropeptide release from primary afferents into the dorsal horn. Two methodological reasons 
could underlie this seemingly contradictory evidence. First is that a small proportion of primary 
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afferents express KOR. The studies discussed above primarily used methods that would activate 
a large number of primary afferents, such as electrical stimulation or capsaicin application. 
Second is that many of these studies were measuring neurotransmitter release in the substantia 
gelatinosa of the rat. Granted there are anatomical differences between the rat and the mouse, but 
the results in previous chapter show the most dense KOR-cre terminal immunoreactivity in 
lamina I or lamina III-V, and less dense in lamina II (which largely corresponds to the substantia 
gelatinosa in the mouse). Thus, the design of several of these studies is such that it would be 
difficult to detect a change, if any, as a result of KOR agonist activity on presynaptic terminals 
because they would likely been have below the level of detection. Given that we can now use the 
KOR-cre allele as a tool to more selectively activate the KOR-expressing population, and can 
record from areas with the densest innervation, it provides a greater opportunity to examine the 
presynaptic effect of KOR agonists more thoroughly. 
In addition to expression at the central terminals, KORs are expressed on the peripheral 
terminals of primary afferents and likely also affect detection and transmission of somatosensory 
information from peripheral tissues. Peripherally-restricted or locally administered KOR agonists 
allow for the investigation of the contribution of peripheral KORs, but also allow for the ability 
to test the effect of activating peripheral KORs using modality selective stimuli in in vivo 
behavioral contexts. Previous studies have shown that systemically administered KOR agonists 
(Simonin et al., 1998); (Schepers, Mahoney, Gehrke, et al., 2008) or a locally administered KOR 
agonist (Vanderah et al., 2004) decrease sensitivity to noxious thermal stimuli in naïve mice, and 
locally administered KOR agonists decreased heat hyperalgesia in an inflammatory state (Cunha 
et al., 2012). Many studies have shown that peripherally-restricted or KOR agonists administered 
locally decrease mechanical hypersensitivity, measured by the paw pressure test, in 
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inflammatory states (Deuis et al., 2015); (Auh & Ro, 2012); (Binder et al., 2001); Machelska 
(Machelska et al., 1999); (Antonijevic et al., 1995); (Stein et al., 1989). One study has tested the 
effect of locally administered KOR agonists on mechanical hypersensitivity, measured by the 
von Frey test, and reported a decrease in mechanical threshold in an inflammatory state (Cunha 
et al., 2012). Alan Cowan and colleagues have shown previously that peripherally-restricted 
KOR agonists decrease scratching induced by histaminergic (Cowan et al., 2015) and non-
histaminergic pruritogens (Inan & Cowan, 2004), supporting the idea that KOR-expressing 
primary afferents are involved in pruritoception as well as nociception. However, the effect of 
peripheral KOR agonists on the modulation of specific chemical algogens or pruritogens hasn’t 
been fully examined, nor has the effect of KOR agonists on mechanical and thermal hyperalgesia 
been examined in a model of post-operative pain, which is a more clinically relevant model than 
the formalin or CFA assays that have been used previously. For the first time, we can use the 
characteristics of KOR-expressing DRG neurons to guide the investigation of KOR agonists’ 
effects on behavioral responses. Therefore, we chose to use both preclinical studies with 
modality selective stimuli as well as a post-operative pain model because they provide an 
opportunity to investigate underlying mechanisms and provide a way to test for drugs that could 
be effective in similar clinical circumstances. 
The experiments below were designed to investigate the effect of KOR activation at 
either the central or peripheral terminals of primary afferents, and to begin to ask how this affects 
the processing of information related to specific somatosensory modalities. First, experiments 
were performed to measure the effect of KOR agonists on neurotransmitter release from primary 
afferents in specific lamina in the spinal cord, with the prediction that KOR agonists would 
decrease glutamate release onto dorsal horn neurons in both laminae. Next, experiments were 
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conducted such that the contribution of central and peripheral KORs could be determined in 
assays that measure the behavioral responses to stimuli of different modalities. To do so, we used 
nalfurafine, a KOR agonist that would act on central and peripheral KORs, as well as two 
peripherally-restricted KOR agonists, ICI204,488 and FE200665. As KOR-expressing primary 
afferents expressed higher levels of multiple transcripts that have previously been shown to be 
involved in mediating thermal sensation and hyperalgesia (such as Trpv1, Ptgir and Trka), we 
predicted that peripherally-restricted KOR-agonists would decrease thermal withdrawal latencies 
at baseline and after injury. In addition, since KOR agonists showed a neurochemical profile 
consistent with their possible involvement in the transmission of chemical nociception and 
pruritoception, we predicted that KOR agonists would decrease behavioral responses to chemical 
algogens and pruritogens. Optogenetics were also used to test the behavioral responses to 
activation of KOR-cre primary afferents to determine if stimulation of these fibers would lead to 
a nocifensive and / or pruritoceptive response. 
3.2 MATERIALS AND METHODS 
3.2.1 Animals 
Mice were given free access to food and water and housed under standard laboratory conditions. 
The use of animals was approved by the Institutional Animal Care and Use Committee of the 
University of Pittsburgh. KOR-cre mice were generated as previously described and are 
maintained on a mixed C57bl/6.129J background (Cai et al., 2016). For electrophysiology 
experiments, KOR-cre mice were mated with C57bl/6 mice or with Ai32 cre-responsive ChR2-
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eYFP reporter mice (The Jackson Laboratory). Unless otherwise noted, 5 - 8 week old male and 
female C57bl/6 mice were used in behavioral experiments. To generate wild-type and KOR-cre-
/- mice for behavioral and immunohistochemical analyses, heterozygous KOR-cre-/+ mice were 
harem mated and age-matched wild-type and KOR-cre-/- male and female offspring from the 
resulting litters were used. 
3.2.2 Electrophysiology 
Mice (4–7 weeks old) were deeply anesthetized and perfused transcardially with ice-cold 
oxygenated (95% O2 and 5% CO2) sucrose-based artificial cerebrospinal fluid (ACSF) (in mM; 
234 sucrose, 2.5 KCl, 0.5 CaCl2, 10 MgSO4, 1.25 NaH2PO4, 26 NaHCO3, 11 Glucose). The 
thoracolumbar spinal cord was tranferred into a small chamber containing ice-cold oxygenated 
sucrose-based ACSF. For lamina I recordings, the dural and pial membranes were carefully 
removed and the spinal cord was pinned onto a Sylgard block with the right dorsal horn facing 
upward with the recording chamber and transferred to the rig. Then, a single parasaggital cut was 
made using a vibratome (Leica) to expose the gray matter, but not cut the dorsal root entry zone, 
then the spinal cord was pinned onto the Sylgard block with the sectioned surface facing upward 
in the recording chamber. For both recording types, the preparation was perfused with normal 
ACSF solution (in mM; 117 NaCl, 3.6 KCl, 2.5 CaCl2, 1.2 MgCl2, 1.2 NaH2PO4, 25 NaHCO3, 
11 glucose) saturated with 95% O2 and 5% CO2 at 32˚C. Tissue was rinsed with ACSF for at 
least 30 min prior to recordings to wash out sucrose. 
Neurons were visualized using a fixed stage upright microscope (BX51WI Olympus 
microscope) equipped with a 40x water immersion objective lens, a CCD camera (ORCA-ER 
Hamamatsu Photonics; XM10-IR, Olympus) and monitor screen. A narrow beam infrared LED 
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(L850D-06 Marubeni, emission peak, 850 nm) was positioned outside the solution meniscus, as 
previously described (Hachisuka et al., 2016). Whole-cell patch-clamp recordings were made 
with a pipette constructed from thin-walled single-filamented borosilicate glass and were filled 
with an intracellular solution containing the following (in mM): 135 K-gluconate, 5 KCl, 0.5 
CaCl2, 5 EGTA, 5 HEPES, 5 MgATP, pH 7.2. Signals were acquired with an amplifier 
(Axopatch 200B, Molecular Devices). The data were low-pass filtered at 2 kHz and digitized at 
10 kHz with an A/D converter (Digidata 1322A, Molecular Devices; Power1401-3, CED) and 
stored using a data acquisition program (Clampex version 10, Molecular Devices or Signal 6, 
CED). The liquid junction potential was not corrected. Cell recordings were made in voltage-
clamp mode at holding potentials of -70mV to record excitatory postsynaptic currents (EPSCs). 
Blue light (GFP filter, centered around 485 nm, Lambda DG-4, Sutter instruments) was applied 
through the objective lens (x40) of the microscope. Light power on the sample was 1.3 mW/mm-
2. The shutter was controlled by Clampex or Signal 6 software. Dynorphin A (Tocris Bioscience, 
3195) and nor-BNI (Tocris Bioscience, 0347) were dissolved in ACSF and applied by 
exchanging solutions via a three-way stopcock.  
3.2.3 Behavioral Assays 
All assays were performed and scored by an experimenter blind to treatment and/or genotype. 
Acute itch and chemical pain assays were videotaped, and subsequently scored by an 
experimenter blind to treatment and/or genotype. Mice were pretreated with vehicle (sterile 
saline; 100μl IP), nalfurafine (20μg/kg; 100μl i.p.; Adooq Bioscience), ICI 204,488 (10mg/kg; 
100μl i.p.; Tocris Bioscience), FE200665 (12mg/kg; 100μl i.p.; provided by YeonSun Lee and 
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Frank Porecca) 15 minutes prior to testing. All testing was performed in the University of 
Pittsburgh Rodent Behavior Analysis Core. 
Optogenetic withdrawal assay 
Mice were placed in a clear plastic container on an elevated wire grid and allowed to 
acclimate for 60 min. The plantar surface of the hindpaw was stimulated with a targeted blue 
light LED beam (coolLED pE-100) for 1 s at either 1 mW, 3 mW, or 10 mW intensity. The 
number of responses out of ten applications per intensity was recorded. Both KOR-cre-/- mice 
and their wild-type littermates received an i.p. injection of AAV9.FLEX.ChR2-
tdTomato.SVRE.WP40 at P1. KOR-cre, RosalslChR2-eYFP mice did not receive an injection. 
Acute itch behavior 
The nape of the neck area was shaved at least twenty-four hours prior to the start of the 
experiment. Mice were placed in a clear plastic container (3.5” x 3.5” x 5”) for observation and 
allowed to acclimate for 30 min. An intradermal injection of chloroquine (200μg/20μl) was made 
into the nape of the neck. The number of scratch bouts was counted during a thirty-minute 
observation period.  
Acute chemical pain behavior 
Mice were placed in a clear plastic container for observation and allowed to acclimate for 
30 min. After acclimatization, an intraplantar (i.pl.) injection of capsaicin (1.5%, 20ul) or acetic 
acid (0.6%, 20ul). The amount of time spent licking the injected paw was quantified during a 
ten- or thirty-minute period, respectively. 
Hargreaves’ test 
Mice were placed in a clear plastic container on a glass floor maintained at 30°C and 
allowed to acclimate for 60 min. A radiant heat beam was then focused onto the hind paw. The 
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latency to hindpaw withdrawal was recorded with 3 trials per animal. Beam intensity was 
adjusted so that at baseline mice displayed a latency of 8 - 12 s. A cut-off latency of 30 s was set 
to avoid tissue damage.  
von Frey test 
Mice were placed in a clear plastic container on an elevated wire grid and allowed to 
acclimate for 60 min. The plantar surface of the hind paw was stimulated with a set of calibrated 
von Frey filaments (0.008 - 6 g). The 50% paw withdrawal threshold was determined using the 
SUDO method (Bonin et al., 2014).  
Post-operative pain assay 
This assay was performed based on the original description in Brennan et al. (Brennan, 
Vandermeulen, & Gebhart, 1996) but adapted for use in mice as described in Pogatzki & Raja, 
(Pogatzki & Raja, 2003). Mice were anesthetized (2.0% for induction and 1.5% for maintenance) 
with isoflurane in a flow of O2, placed in a prone position on a heating pad covered with a blue 
fiber disposable towel. Laboratory tape was used to secure the left hind paw, which was then 
sterilized with betadine solution and wiped clean with sterile gauze. A 5 mm incision extending 
from the proximal edge of the heel towards the toes was made with a no. 11 scalpel. The incision 
was made through the glabrous skin, fascia and underlying plantaris muscle (leaving muscle 
origin intact), taking care not to cut the underlying ligaments. A single nylon mattress suture was 
used to close the wound and antibiotic ointment was applied to the area of the incision. Mice 
recovered from aneasthesia within 5 min and were returned to their home cage. Two and twenty-
four hours after the incision, mice were placed in clear plastic containers either on an elevated 
wire grid for von Frey testing or on a glass floor for Hargreaves’ testing. Mechanical sensitivity 
was recorded as the number of withdrawal responses (out of 10) to a single von Frey fiber (vF # 
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3.61, 0.4g) applied to the plantar surface of the paw adjacent to the incision. Thermal sensitivity 
was measured using the Hargreaves’ test as described above, but the radiant heat beam was 
focused on the hindpaw near the area of the incision. Baseline measurements were made for both 
the von Frey and Hargreaves’ tests twenty-four hours prior to the incision. Mice with wound 
dehiscence or puss around the incision at the time of behavioral testing were removed from the 
experiment. 
3.3 RESULTS 
3.3.1 A KOR agonist decreases glutamate release from primary afferents in the 
superficial and deep dorsal horn 
In an attempt to address the function of KOR on primary afferents, first the effect of KOR 
activation at the central terminals in the spinal dorsal horn was investigated. As KOR-cre 
terminals were most dense in the very superficial dorsal horn and in the deeper dorsal horn, and 
less dense in the lamina propria, dorsal horn neurons in either lamina I or lamina III were 
targeted in the following experiments. To address the effect that KOR activation had on 
somatosensory transmission from primary afferents to second order neurons in the spinal cord, 
an experiment was designed that would measure the effects of KOR agonist dynorphin on the 
amplitude of light-evoked excitatory post-synaptic potentials (eEPSCs) observed upon 
optogenetic activation of KOR-cre afferents. Optogenetic stimulation was chosen over electrical 
root stimulation because selectively stimulating a smaller population of primary afferents that 
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were more likely to express KOR allowed for increased likelihood of detecting the effect of 
dynorphin. 
To confirm the role of KOR on the central terminals of peptidergic afferents, the ex-vivo 
spinal preparation was used, which facilitates visualization of lamina I neurons for targeted 
whole cell patch clamp recordings (Figure 14A) (Hachisuka et al., 2016). Further, an advantage 
of this preparation is that it allows for an increased maintenance of spinal cord circuitry, and 
hence data collected are representative of a more complete dorsal horn environment than that 
collected using spinal cord slices. First, lamina I neurons that likely received monosynaptic input 
from KOR-cre afferents were identified based on eEPSC latency and absence of failure 
following optogenetic stimulation of KOR-cre afferent input. Next, paired-pulse blue light 
stimulation was applied through the microscope objective and these recordings were used to 
analyze the effect of dynorphin. These experiments revealed that dynorphin significantly and 
reversibly decreased the first peak eEPSC amplitude and increased the paired-pulse ratio that 
was observed upon optogenetic stimulation of KOR-cre afferents (Figures 14B, 14C and 14D). 
Similar results were observed when the experiments were repeated in the presence of naltrexone 
(1 m), indicating that they were not due to a dynorphin-induced activation of MOR (Figures 
15A, 15B and 15C). These findings suggest KOR activation reduces glutamate release from the 
central terminals of KOR-cre primary afferents in the superficial dorsal horn. 
To investigate whether the KOR-cre afferents that target the deep dorsal horn were 
similarly modulated by KOR signaling, a modified ex-vivo spinal cord preparation was 
developed by Yu Omori in which a single parasagittal cut in one hemisphere of the spinal cord 
was performed in order to target neurons in LIII for patch-clamp recordings (Figure 14E). For 
these experiments, optogenetic stimulation of the dorsal root was performed to stimulate KOR-
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cre positive afferents. To identify neurons in the dorsal horn that likely received monosynaptic 
input from these fibers, the absence of failure to elicit an EPSC following optogenetic 
stimulation of KOR-cre afferent input was used. Just as was found in lamina I, treatment with 
dynorphin caused a significant and reversible decrease in the first peak amplitude of eEPSCs, 
which corresponded to a significant increase in the paired-pulse ratio (Figures 14F, 14G and 
14H). Similar results were also obtained in the presence of naltrexone (1 m) to block MOR 
(Figures 15D, 15E and 15F). These findings suggest that KOR-cre afferents that target the deep 
dorsal horn (possibly including LTMRs) also show reduced glutamate release upon activation of 
KOR. Thus, KORs on the central terminals of primary afferents mediate presynaptic inhibition in 
both the superficial and deep dorsal horn. 
 
 
Figure 14. KOR activation reduces glutamate release from primary afferents that target lamina I and lamina 
III 
A. Schematic illustrating the experimental set-up used to record from lamina I dorsal horn neurons while 
optogenetically stimulating KOR-cre primary afferent terminals. KOR-cre primary afferents were infected with a 
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Cre-dependent virus encoding channel rhodopsin (AAV.FLEX.ChR2-tdTomato; IP, P1) enabling selective 
activation of KOR-cre primary afferent terminals upon application of blue light to the spinal cord. 
B. Representative trace of whole-cell patch clamp recording from a lamina I neuron at baseline (black) and during 
bath application of dynorphin (1 μM; blue). Two 5 ms pulses of blue light were given 100 ms apart to elicit light-
evoked EPSCs.  
C - E. Quantification of the relative amplitude of the first eEPSC (C), the relative amplitude of the second eEPSC 
(D) and paired-pulse ratio (E) at baseline (white), upon application of dynorphin (1 μM; blue), and following wash 
(gray). Dynorphin caused a significant decrease in the amplitude of the first eEPSC compared to baseline in lamina I 
neurons and a significant increase in the paired-pulse ratio compared to baseline, which was reversible (One-way 
ANOVA and Dunnett’s multiple comparison’s test, p < 0.05; n = 14 cells). Data are presented as mean ± SEM. 
There was no significant change in the 2nd peak amplitude during dynorphin application compared to baseline (p = 
0.1; data not shown) 
F. Schematic illustrating the experimental set-up used to record from lamina III dorsal horn neurons while 
optogenetically activating KOR-cre primary afferents. KOR-cre, ROSAlslChR2-eYFP mice were used for these 
experiments, and therefore blue light stimulation was applied to the dorsal root in order to selectively activate KOR-
cre primary afferents and not KOR-expressing spinal neurons. 
G. Representative trace of whole-cell patch clamp recording from a lamina III neuron at baseline (black) and during 
bath application of dynorphin (1 μM; green). Two 5 ms pulses of blue light were given 100 ms apart to elicit light-
evoked EPSCs.  
H - J. Quantification of the first eEPSC relative amplitude (H), second eEPSC relative amplitude (I)and paired pulse 
ratio (J) at baseline (white), upon application of dynorphin (1 μM; green), and following wash (gray). Dynorphin 
caused a significant decrease in the amplitude of the first eEPSC and a significant increase in the paired-pulse ratio 
compared to baseline in lamina III neurons, which was reversible (One-way ANOVA and Dunnett’s multiple 
comparison’s test, p < 0.05; n = 6 cells). Data are presented as mean ± SEM. There was no significant change in the 




Figure 15. Dynorphin-mediated inhibition of glutamate release from KOR-expressing afferents is not 
inhibited by naltrexone 
A. Representative trace of whole-cell patch clamp recording from a lamina I neuron at baseline (black) and during 
bath application of dynorphin (1 μm) + naltrexone (1 μm) (blue). Two 5 ms pulses of blue light were given 100 ms 
apart to elicit light-evoked EPSCs. 
B - D. Quantification of the 1st eEPSC relative amplitude, 2nd eEPSC relative amplitude, and relative paired pulse 
ratio during baseline (white), drug (blue), and wash (gray) conditions in recordings from lamina I dorsal horn 
neurons following blue light stimulation of KOR-cre positive primary afferent terminals in KOR-cre + FLEX.ChR2 
IP at P1. There was a significant decrease in 1st peak amplitude during dynorphin + naltrexone application compared 
to baseline in lamina I neurons (B). There was no significant change in 2nd peak amplitude during dynorphin + 
naltrexone application compared to baseline in lamina I neurons (C). There was a significant increase in the paired 
pulse ratio during dynorphin + naltrexone application compared to baseline in lamina I neurons (D). Data are 
presented as mean ± SEM. * p < 0.05, one-way ANOVA followed by Dunnett’s multiple comparison’s test, n = 15 
cells.  
E. Representative trace of whole-cell patch clamp recording from a lamina III neuron at baseline (black) and during 
bath application of dynorphin (1 μm) + naltrexone (1 μm) (green). Two 5 ms pulses of blue light were given 100 ms 
apart to elicit light-evoked EPSCs. 
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F - H. Quantification of the 1st eEPSC relative amplitude, 2nd eEPSC relative amplitude, and relative paired pulse 
ratio during baseline (white), drug (green), and wash (gray) conditions in recordings from lamina III dorsal horn 
neurons following blue light stimulation of the dorsal root in KOR-cre RosalslChR2-eYFP mice. There was a significant 
decrease in 1st peak amplitude during dynorphin + naltrexone application compared to baseline in lamina III neurons 
(F). There was no significant change in 2nd peak amplitude during dynorphin + naltrexone application compared to 
baseline in lamina III neurons (G). There was a significant increase in the paired pulse ratio during dynorphin + 
naltrexone application compared to baseline in lamina III neurons (G) Data are presented as mean ± SEM. * p < 
0.05, one-way ANOVA followed by Dunnett’s multiple comparison’s test, n = 6 cells.  
3.3.2 Optogenetic activation of KOR-cre primary afferents elicits withdrawal 
Given the peptidergic nature of many KOR-expressing afferents, it seemed likely that selective 
activation of this population might elicit nocifensive withdrawal behaviors. To test this idea 
directly, channelrhodopsin 2 (ChR2) was expressed in KOR-cre mice using either a virus 
(FLEX.ChR2-tdt) or the Ai32 allele (Figure 16A). Blue light LED stimulation (470 nm; 1 s) was 
applied to the glabrous hind paw skin at one of three intensities (1 mW, 3 mW, or 10 mW). In 
control littermates (that had received the Cre-dependent virus but lacked KOR-cre), blue light 
stimulation did not elicit a withdrawal response at any intensity tested (Figure 16B; black line). 
In contrast, when ChR2 was expressed in KOR-cre afferents using either a virus or an allele, 
3mW and 10mW light stimulation of the hind paw elicited a robust withdrawal response that was 
frequently accompanied by either jumping or licking/biting of the hind paw, or both (Figure 16B; 
blue lines and bars). These findings reveal that blue light induced activation of ChR2-expressing 




Figure 16. Optogenetic activation of KOR-cre afferents cause nocifensive withdrawal behavior 
A. Schematic of optogenetic withdrawal experimental design. Blue light (470 nm) LED stimulation was applied to 
the glabrous hindpaw for 1 sec. Three different groups were tested; KOR-cre; ROSAlslChR2 mice, KOR-cre mice + 
FLEX.ChR2 (IP at P1), and the wild-type littermates (WT) + FLEX.ChR2 (IP at P1).  
B. The percentage of mice showing withdrawal upon optogenetic stimulation at three different LED intensities (1 
mW, 3 mW, and 10 mW). Data are presented as mean ± SEM (n = 4 - 6 mice/group). 
3.3.3 Peripherally-restricted KOR agonists inhibit chemical pain and itch behaviors, but 
no thermal thresholds 
Given that activation of KOR-expressing afferents appeared to be aversive, we next investigated 
whether inhibition of these cells with a KOR agonist would reduce behavioral responses to 
noxious or pruritic stimuli. To do so, we compared the effects of nalfurafine, a centrally-
penetrating KOR agonist (Endoh et al., 2001); (Nagase et al., 1998), to those of either 
ICI204,488 or FE200665, two peripherally restricted KOR agonists that have extremely limited 
ability to cross the blood brain barrier (Figure 7C) (Shaw, Carroll, Alcock, & Main, 1989); 
(Vanderah et al., 2008). For these experiments, mice of both sexes were used and, since no 
difference between sexes was observed, data were pooled.  
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Following an intraplantar (IPL) injection of capsaicin (20 μL of 1.5% capsaicin), mice 
treated with any of the three KOR agonists showed a significant decrease in the time spent 
licking the injected hind paw (Figure 17A) compared to mice treated with vehicle. Similarly, all 
three KOR agonists reduced the time that mice spent licking the injected hind paw following an 
IPL injection of acetic acid (20 μL of 0.6% AA; Figure 17C). Furthermore, both centrally active 
and peripherally-restricted KOR agonists reduced scratching behavior in response to intradermal 
chloroquine (200 μg in 20 μL; Figure 17D). Importantly, these effects were due to the action at 
KOR, rather than an off-target effect of the drugs. To test the specificity of these agonists, we 
tested their effects in homozygous KOR-cre knockin mice (i.e. KOR -/-). We found that 
nalfurafine decreased chloroquine-induced scratching in wild-type littermates but not in KOR-
cre homozygous mice (Figure 18A). Further, we observed that nalfurafine increased paw 
withdrawal latency (PWL) in the Hargreaves test in wild-type littermates but not in KOR-cre 
homozygous mice (18B). Similarly, we observed that ICI204,448 or FE200665 did not decrease 
chloroquine-induced scratching in mice that lacked KOR (Figures 18C - 18D), but did 
significantly reduce chloroquine-induced scratching in wild-type littermates. Taken together, 
these results suggest that peripherally-restricted KOR agonists are sufficient to decrease acute 




Figure 17. Peripherally-restricted KOR agonists decrease chemical pain and itch 
A. Schematic diagram illustrating kappa agonists used in behavioral assays in D - J. Nalfurafine acts both centrally 
and peripherally, whereas ICI204,488 and FE200665 are peripherally restricted KOR agonists. Nalfurafine (Nalf; 
200 μg/kg), ICI204,448 (ICI; 10 mg/kg), and FE200665 (FE; 12 mg/kg) were given IP 15 minutes prior to 
behavioral testing. All data are presented as mean ± SEM and colored shapes represent data points from individual 
animals. 
B. Capsaicin-induced licking behavior (20 μL, intraplantar, 1.5%) was significantly reduced by Nalf, ICI, or FE 
(One-way ANOVA with Dunnett’s multiple comparison’s test, p < 0.001; n = 10 mice/group). 
C. Acetic Acid-induced licking behavior (20 μL intraplantar, 0.6%) was significantly reduced by Nalf, ICI, or FE 
(One-way ANOVA with Dunnett’s multiple comparison’s test, p < 0.05; n = 10 mice/group). 
D. Chloroquine-induced scratching behavior (20 μL intradermal, 200 μg) was significantly reduced by Nalf, ICI, or 




Figure 18. The effects of nalfurafine, ICI204,488 and FE200665 on itch and pain behaviors are specific to 
KOR 
Nalfurafine (Nalf, 200 μg/kg), ICI204,488 (ICI, 10 mg/kg), or FE200665 (FE, 12 mg/kg) were given IP 15 
minutes prior to the start of the behavioral assays. KOR mutant mice, which are homozygous for the KOR-
cre allele, and their wild-type littermates were used for these experiments. All data are presented as mean ± 
SEM and colored shapes represent data points from individual mice.  
A. Nalfurafine significantly decreased chloroquine-induced scratching behavior (20 μl intradermal, 200 μg) 
in wild-type mice (*, p < 0.05, two-way ANOVA with General Linear Hypothesis Test). In KOR mutant 
mice, nalfurafine had no significant effect (NS, p > 0.05). n = 7 – 8 mice/group. 
B. Nalfurafine significantly paw withdrawal latency to thermal heat (Hargreaves’ test) in wild-type mice, 
(*, p < 0.001, two-way ANOVA with General Linear Hypothesis Test). In KOR mutant mice, nalfurafine 
had no significant effect (NS, p > 0.05). n = 7 – 8 mice/group. 
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C. ICI204,448 significantly decreased chloroquine-induced scratching behavior (20 μl intradermal, 200 μg) 
in wild-type mice (*, p < 0.001, two-way ANOVA with General Linear Hypothesis Test,). In KOR mutant 
mice, ICI204,448 had no significant effect (NS, p > 0.05). n = 9 mice/group. 
D. FE200665 significantly decreased chloroquine-induced scratching behavior (20 μl intradermal, 200 μg) 
in wild-type mice, but not in KOR mutant mice (*, p < 0.01, two-way ANOVA with General Linear 
Hypothesis Test,). In KOR mutant mice, ICI204,448 had no significant effect (NS, p > 0.05). n = 8 – 12 
mice /group. 
 
To determine the modality selectivity of the responses to peripherally-restricted KOR 
agonists, their effects on mechanical and thermal sensitivity were investigated, both under naïve 
conditions and in a model of post-operative pain. In naïve mice, none of the KOR agonists 
influenced paw withdrawal threshold to the application of von Frey filaments (Figure 19A). 
Furthermore, only nalfurafine, but not the peripherally restricted agonists ICI204,448 or 
FE200665, inhibited thermal responsivity in the Hargreaves’ assay (Figure 19B).  
Following injury, such as an incision during surgery, nociceptor activation and/or 
sensitization (Pogatzki, Vandermeulen, & Brennan, 2002); (Brennan, 2011) can drive ongoing 
pain and hypersensitivity to mechanical and thermal stimuli (Brennan et al., 1996). Analyzing 
the effect of injection of a receptor-specific ligand (such as the assays used in Figure 17), while 
useful to study specific mechanisms, does not recapitulate the etiology and development of tissue 
conditions causing pain following an incision. Therefore, the Brennan incision model (Brennan 
et al., 1996) modified for use in mice (Pogatzki & Raja, 2003) was used in an effort to 
investigate whether KOR agonists might be useful for the management of post-operative pain. 
With this model, we found that nalfurafine, ICI204,488, or FE200665 inhibited mechanical 
hypersensitivity at two hours following incision of the hind paw (Figure 19C), but not at twenty-
four hours following incision (Figure 19E). Only nalfurafine, but not the peripherally restricted 
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agonists, inhibited thermal hypersensitivity in the Brennan model (Figure 19D and 19F) at two 
hours and twenty-four hours following incision. Whereas nalfurafine attenuated both thermal and 
mechanical hypersensitivity, peripherally-restricted KOR agonists were only sufficient to inhibit 




Figure 19. Peripherally-restricted KOR agonists decrease acute mechanical hypersensitivity following 
incision, but not thermal thresholds 
A. Paw withdrawal threshold (PWT) as measured by the von Frey test was not significantly changed by Nalf, ICI, or 
FE (One-way ANOVA, p = 0.8; n = 9 - 10 mice/group). 
B. Nalfurafine significantly increased paw withdrawal latency (PWL) as measured by the Hargreaves’ test, but ICI 
and FE had no effect on PWL (One-way ANOVA with Dunnett’s multiple comparison’s test (* p < 0.05; n = 12 - 16 
mice/group). 
C. Mechanical hypersensitivity, measured 2 hours after an incision of the hind paw, was significantly reduced by 
Nalf, ICI, or FE (One-way ANOVA with Dunnett’s multiple comparisons test, *, p < 0.001; n = 7 – 9 mice/group). 
Mechanical sensitivity was recorded as the number of withdrawal responses (out of 10) to a single von Frey fiber 
(vF # 3.61, 0.4g) applied to the plantar surface of the paw adjacent to the incision. Data are normalized to a baseline 
measure recorded 24 hours prior to the incision. 
D. Thermal hypersensitivity, measured 2 hours after an incision of the hindpaw, was significantly reduced by Nalf 
(One-way ANOVA with Dunnett’s multiple comparison’s test, *, p < 0.01), whereas ICI or FE had no significant 
effect (p > 0.05; n = 8 – 9 mice/group). Data are normalized to a baseline measure recorded 24 hours prior to the 
incision. 
E. Mechanical hypersensitivity, measured 24 hours after an incision of the hind paw, was not significantly changed 
by Nalf, ICI, or FE (One-way ANOVA with Dunnett’s multiple comparison’s test, *, p = 0.14; n = 7 – 9 
mice/group). Data are normalized to a baseline measure recorded 24 hours prior to the incision. 
F. Thermal hypersensitivity, measured 24 hours after an incision of the hindpaw, was significantly reduced by Nalf 
(One-way ANOVA with Dunnett’s multiple comparison’s test, p < 0.05), whereas ICI or FE had no significant 




The experiments within this chapter were aimed at determining how KOR agonists affect 
somatosensory transmission at primary afferent central terminals and at the level of the 
periphery. Whole-cell patch clamp recordings in dorsal horn neurons in both lamina I and lamina 
III demonstrated that KOR agonists could decrease glutamate release from primary afferent 
fibers. Activation of KOR-cre afferents using optogenetics induced a withdrawal response 
consistent with pain sensation supporting the idea that these afferents are involved in 
transmitting nociceptive information. Complementary results using KOR agonists to decrease 
activity of KOR-expressing afferents (instead of using optogenetics to activate KOR-expressing 
afferents) showed a decrease in pain- and itch-related behaviors. Behavioral assays showed that 
peripheral KOR agonists were sufficient to decrease pain- and itch-related behaviors caused by 
chemical irritants, while peripherally and centrally acting KOR agonists decreased mechanical 
hypersensitivity in a model of post-operative pain. Surprisingly, only a KOR agonist that 
penetrates the blood-brain barrier, nalfurafine, decreased noxious thermal sensitivity either in 
naïve mice or in a model of post-operative pain. These data suggest that there are multiple sites 
of action for KOR agonists (endogenous or exogenous) to modulate somatosensory information, 
and support further exploration of peripherally-restricted KOR agonists in the treatment of pain 
and itch conditions. 
In contrast to several other publications that did not observe an effect of KOR agonists on 
primary afferent release of neurotransmitter into the spinal cord (Ikoma et al., 2007); (Kohno et 
al., 1999); (Ueda et al., 1995), we observed a KOR agonist-mediated decrease in evoked EPSC 
amplitude in dorsal horn neurons upon optogenetic stimulation of KOR-cre afferents. As 
mentioned in the introduction of this chapter, our characterization of KOR-expressing primary 
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afferent allowed for more specific methodological design that would give us an advantage to 
detect this phenomenon, if it was indeed occurring. To the best of our knowledge, this is the first 
time this effect has been reported in both the superficial and deeper dorsal horn. Terminals in 
these different laminae are likely to be functionally distinct in that afferents targeting lamina I 
are more likely to transmit nociceptive information and those in deeper lamina (II-V) are more 
likely to transmit low-threshold mechanosensation. However, this conclusion cannot be 
definitely reached without more specific experiments (see Section 4.6 Future Directions). 
Based on the effects of peripherally-selective KOR agonists, it might have been expected 
that optogenetic activation of KOR-cre afferents would result in both pain and itch behaviors. 
However, we observed withdrawal behaviors that are more consistent with nocifensive 
withdrawal than itch-related behaviors. Because pain generally inhibits itch (for review, see 
(Schmelz, 2005)), an alternative possibility is that itch might be occluded upon co-activation of 
KOR-cre nociceptors and pruritoceptors. In the experiment described above, activation of KOR-
cre afferents that innervate the glabrous hind paw resulted in behaviors that are consistent with a 
nocifensive response (withdrawal, jumping and licking/biting behaviors). Alternatively, itch-
associated behaviors may have been difficult detect since mice cannot scratch glabrous skin, 
which was the site of LED stimulation. Consistent with this possibility, when LED stimulation 
was targeted KOR-expressing afferents that innervate the ear, we observed abrupt withdrawal 
from the laser that was sometimes accompanied by ear-directed scratching with the hindlimb 
(personal observation), a behavior that is at least consistent with pruritoception. Since 
peripherally-restricted KOR agonists reduce chemical pruritogen-induced scratching, it is 
possible that a subset of KOR-expressing fibers that innervate the skin are involved in mediating 
itch; if so, however, it remains to be resolved which KOR-expressing afferents are involved.  
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In naïve mice, neither nalfurafine nor the peripherally-restricted KOR agonists affected 
mechanical threshold as measured by the von Frey test. Because the withdrawal threshold in the 
von Frey test is likely already at threshold, though, it is likely that it would be difficult to 
measure a KOR-mediated increase in mechanical threshold using this method. Future studies 
could investigate a KOR agonist driven effect on baseline mechanical sensitivity using a method 
such as the paw pressure test. The observation that the peripherally-restricted KOR agonists 
didn’t affect mechanical threshold in this assay isn’t overly surprising, as KOR-cre fibers did not 
overlap substantially with IB4-expressing C-fibers nor show overlap with A-fibers innervating 
Meissner’s corpuscles or Merkel cells in the glabrous skin. Before conducting the experiment, 
we predicted that nalfurafine would have had an effect on mechanical sensitivity because a 
recent study reported that ablation of dynorphin-cre interneurons in the spinal cord led to an 
increase in sensitivity to static and dynamic mechanical sensitivity using von Frey and brush 
assays, respectively (Duan et al., 2014). The authors interpreted these results as a role for 
dynorphin-cre interneurons in the inhibition of low-threshold mechanosensation, but did not 
investigate whether this effect was due to release of dynorphin or GABA/glycine. The results 
here are consistent with the interpretation that perhaps dynorphin release in the spinal cord does 
not play a large role in low-threshold mechanical sensitivity, at least not in the glabrous skin, and 
the phenotype observed after ablation of dynorphin-cre interneurons may more heavily involve 
GABA/glycine signaling than dynorphin signaling. Although the KOR agonists did not affect 
mechanical sensitivity in the experiment described here, the von Frey test used is measuring low-
threshold mechanical sensitivity. Future experiments could determine the effects of KOR 
agonists on mechanical sensitivity in the naïve state, specifically within the noxious range, by 
using a paw pressure assay. This type of assay would also likely involve afferents innervating 
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deeper tissues as well as cutaneous afferents, unlike the von Frey assay which activates 
cutaneous fibers.  
Interestingly, nalfurafine and the peripherally-restricted KOR agonists did decrease 
mechanical hypersensitivity at 2 hours after an incision of the hind paw in the model of post-
operative pain. A possible mechanism underlying this observation is that KOR-expressing 
afferents are sensitized following the incision and KOR agonists prevented or decreased the level 
of this sensitization. Primary afferent sensitization is defined as a gain of mechanical sensitivity, 
decreased threshold to mechanical stimuli, an increase in background activity, an increased 
responsiveness to the same stimuli, or an increase in the size of the receptive field. Brennan and 
colleagues have previously compared the responses of primary afferents to mechanical 
stimulation before and after incision. They report the primary mechanism of mechanical 
sensitization at 45 min post-incision observed across fiber types (Aδ, C fibers, or mechanically-
insensitive fibers) was an expansion of the receptive field (Hamalainen, Gebhart, & Brennan, 
2002). Thus, expansion of the receptive field of multiple fibers could cause an increase in the 
number of fibers activated during the presentation of a punctate mechanical stimulus. If a great 
enough proportion of these fibers express KOR, it could be that KOR agonists were sufficient to 
mitigate the resulting spatial summation and increased mechanical sensitivity. Alternatively, 
afferents responding to the mechanical stimuli before and after the incision could start expressing 
KOR after injury, and hence the KOR agonists could potentially decrease the responsiveness of 
these fibers. Consistent with this possibility, previous studies have shown an increase in KOR 
mRNA and protein levels in the DRG following injury (Caram-Salas et al., 2007); (Zambelli et 
al., 2014); (Obara et al., 2009); (Puehler et al., 2006). However, it is unclear if this increase was 
within primary afferents that already express the KOR, due to de novo expression in other 
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primary afferents, or both (future studies investigating this question will be considered in section 
4.0 General Discussion). 
In contrast to the mechanical sensitivity assay, nalfurafine did decrease thermal 
sensitivity in naïve mice as measured by the Hargreaves’ test. The peripherally-restricted KOR 
agonists did not change thermal sensitivity suggesting the effect of nalfurafine was due to action 
at central KORs. The observation that the peripherally-restricted KOR agonists did not affect 
thermal sensitivity was surprising, as many KOR-cre positive afferents expressed TRPV1-IR and 
all Oprk1-expressing peptidergic afferents tested expressed Trpv1 mRNA. TRPV1 is known to 
be activated by heat stimuli into the noxious range (Caterina et al., 1997), and ablation of 
TRPV1-expressing fibers decreases thermal sensitivity (Cavanaugh et al., 2009). However, the 
TRPV1 channel is known to be activated by other stimuli as well such as protons and vallinoid 
compounds like capsaicin (Caterina et al., 1997). Further, a larger proportion of TRPV1-
expressing afferents target deeper tissues which are likely to be less involved in detecting 
noxious heat and may be more involved in detecting protons, vallinoids, or be a downstream 
target interacting with other membrane proteins (Christianson, McIlwrath, Koerber, & Davis, 
2006). Therefore, the subset of TRPV1- and KOR-expressing afferents could be tuned to 
transmit information regarding the chemical milieu of the surrounding tissue rather than 
temperature.  
Consistent with this interpretation, only nalfurafine decreases thermal hypersensitivity 
following an incision of the hind paw in the post-operative pain model. This suggests that the 
effect was driven by nalfurafine’s action at central KORs, and that primary afferents expressing 
KOR are not greatly involved in transmitting information about noxious heat in a naïve state nor 
post-injury. This contrasts with results of previous studies investigating the effect of peripheral 
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KOR activation on thermal sensitivity either in naïve mice (Vanderah et al., 2004) or in an 
inflammatory state (Cunha et al., 2012). These studies gave local injections of KOR agonists, 
though, which could potentially underlie the difference. It could be that most of the KOR-
expressing fibers are more tuned for chemical detection, but some of them do transmit 
temperature information and a local injection could be more effective at inhibiting these fibers, 
whereas a systemic injection of a peripherally-restricted agonist may not. 
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4.0  GENERAL DISCUSSION 
4.1 OVERVIEW 
This study expanded our knowledge of how the kappa opioid receptor system modulates 
somatosensory information and built a foundation for future exploration of this system as a 
potential target for the treatment of pain and itch conditions. The experiments described herein 
investigated the primary afferent cell types that express KOR through characterization of their 
anatomical, neurochemical, and transcriptional profiles using a combination of 
immunohistochemistry, viral tracing, and single cell RT-PCR in a KOR-cre mouse line. Building 
upon this information, additional experiments investigated if KOR agonists could influence 
somatosensory transmission either centrally, peripherally or both using either in vitro physiology 
or in vivo behavioral models.  
We demonstrated that KOR is expressed on at least two distinct subtypes of primary 
afferent fibers that differ in both their anatomical and neurochemical profiles. One is a group of 
peptidergic putative nociceptors and/or pruritoceptors that express significantly higher levels of 
particular mRNA transcripts classically expressed in peptidergic afferents, and target multiple 
tissues throughout the body. Another is a group of putative myelinated LTMRs that form 
specialized lanceolate or circumferential endings around hair follicles in the skin. These two 
groups’ central terminals targeted distinct lamina in the spinal dorsal horn, either the very 
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superficial lamina or the deeper dorsal horn, respectively. Further, using optogenetics, we found 
that KOR agonists decrease evoked EPSC amplitude resulting from optogenetic activation of 
KOR-expressing primary afferent terminals in both the superficial and deeper dorsal horn. 
Finally, we tested the effect of either a centrally and peripherally acting KOR agonists or 
peripherally restricted agonists in multiple behavioral models of pain and itch. Importantly, we 
demonstrated that each of the KOR agonists we used was specific to the KOR, as each drug had 
no effect in KOR homozygous mice. Peripherally-restricted KOR agonists decreased responses 
to chemical algogens and pruritogens, but only were sufficient to decrease mechanical, not 
thermal, hypersensitivity in a model of postoperative pain. In summary, these experiments define 
at least two subgroups of primary afferent neurons expressing KOR (Figure 8), and provide 
insight into how KOR agonists act to alter somatosensory transmission. 
 
 
Figure 20. KOR is expressed by peptidergic afferents innervating multiple tissue types as well as a subset of 
LTMRs that target hair follicles 
Schematic of the primary afferent subtypes that express the KOR. One is a subset of LTMRs that form lanceolate 
and circumferential endings around hair follicles in the skin (blue fibers). Another is a subset of peptidergic afferents 
(red fibers) that expresses particularly high transcript levels of classic peptidergic markers such as CGRP and 
Substance P, and these fibers innervate multiple tissue types including the skin, muscle, and viscera.   
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4.2 POSSIBLE MECHANISMS UNDERLYING KOR AGONISTS’ EFFECTS IN A 
MODEL OF POST-OPERATIVE PAIN 
The study we performed investigating KOR agonist effects on hypersensitivity to a mechanical 
or thermal stimulus demonstrated that peripherally-restricted KOR agonists decreased 
mechanical, but not thermal, hypersensitivity. Previous experiments measuring afferent activity 
in the incision model by Brennan and colleagues can give us some insight into the mechanism 
underlying this observation and inspire ideas for experiments to test future hypotheses. Skin 
incision alone has been shown to be sufficient to cause hypersensitivity to evoked behaviors 
caused by mechanical and thermal stimuli (J. Xu & Brennan, 2009). Even though incision of 
both the skin and deeper tissue was made, the experiments described herein involved behavioral 
assays that primarily stimulate cutaneous tissue. Due to the nature of stimulus application in the 
von Frey (and Hargreaves tests), we are only measuring the effect of KOR agonists on cutaneous 
afferents. Future experiments of interest include using an assay that would also stimulate deeper 
tissues, such as a paw pressure assay, which could test more specifically the effects of KOR 
agonists on pain-related behaviors caused by stimulation of superficial and deep tissues. Several 
studies have reported mechanical sensitization of muscular, visceral, or articular afferents after 
injury or in inflammatory states (Ustinova, Fraser, & Pezzone, 2006); (J. L. Ross, Queme, Shank, 
Hudgins, & Jankowski, 2014); (Schaible & Schmidt, 1985); (Neugebauer, Schaible, & Schmidt, 
1989). As KOR-expressing primary afferents target multiple tissue types and not only cutaneous 
tissue, it is possible that peripherally-restricted KOR agonists could also decrease mechanical 
hypersensitivity in deeper tissues after injury as well.  
After an incision of the hind paw in rats, Brennan and colleagues have shown an increase 
in spontaneous activity at the level of both the primary afferents and in dorsal horn neurons, that 
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wasn’t observed until approximately one day following incision. The spontaneous activity in 
dorsal horn neurons following an incision is still largely dependent on primary afferent input, as 
bupivacaine treatment of the incised tissue decreased the level of spontaneous activity in dorsal 
horn neurons (J. Xu & Brennan, 2009); (Brennan, 2011). They have shown that deep tissue 
incision, compared to an incision of the skin alone, was necessary to induce spontaneous activity 
of both the primary afferents and dorsal horn neurons as well as spontaneous pain behaviors (J. 
Xu & Brennan, 2009); (J. Xu & Brennan, 2010). Therefore spontaneous activity of primary 
afferents, in particular cutaneous afferents, is likely not a major driver of hypersensitivity to 
evoked pain behaviors. Future experiments measuring both the effect KOR agonists have on 
spontaneous activity in primary afferents of deeper tissues and ongoing pain behaviors (in 
addition to evoked pain behaviors) following an incision would further inform their therapeutic 
potential in surgical procedures that incise deeper tissues. However, dilute capsaicin treatment 
after incision reduces heat hypersensitivity and spontaneous pain behaviors, but not mechanical 
hypersensitivity, suggesting these may be separate mechanisms (Kang, Wu, Banik, & Brennan, 
2010). Brennan and colleagues have also reported that intraplantar injection of TrkA IgG or anti-
NGF increased heat hyperalgesia and spontaneous pain behaviors, but did not change mechanical 
thresholds (Zahn, Subieta, Park, & Brennan, 2004); (Banik, Subieta, Wu, & Brennan, 2005).  
Since peripherally-restricted KOR agonists decreased mechanical hypersensitivity, but not heat 
hypersensitivity, one might predict that peripherally-restricted KOR agonists would also 
therefore not affect spontaneous pain behaviors.  
Interestingly, in the experiments described herein, at two hours post-incision, peripheral 
KOR agonists were sufficient to cause a decrease in mechanical hypersensitivity, but the 
decrease after treatment with a peripheral KOR agonists was lost at twenty-four hours post-
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incision. As spontaneous activity wasn’t observed post-incision until one day later and not in 
skin incision alone, these data further support the conclusion that spontaneous activity wasn’t the 
mechanism underlying evoked mechanical hypersensitivity to von Frey filaments. Other 
potential mechanisms underlying hypersensitivity of evoked behavioral responses are decreased 
response threshold of primary afferents, increased response of primary afferents, and / or an 
increase proportion of primary afferents responding to a given stimulus (Brennan, 2011; 
Hamalainen et al., 2002). Physiological recordings of primary afferents fibers in mice following 
an incision injury could measure the influence of peripheral KOR agonists on each of these 
parameters to define the mechanism(s) of action for the reduction of hypersensitivity to 
mechanical stimuli within the first hours following incision, particularly in cutaneous afferents. 
Experimental models in humans evaluating the mechanisms of sensitization following an 
incision have supported the idea that primary hypersensitivity (in the area of tissue damage) is 
mediated by primary afferent activity, but secondary hypersensitivity (outside the area of tissue 
damage) involves other mechanisms, such as central sensitization (Kawamata, Takahashi, et al., 
2002), (Kawamata, Watanabe, et al., 2002). Therefore, if peripheral KOR agonists can decrease 
primary afferent responsiveness to evoked stimuli in the area of tissue injury, it is promising sign 
that these drugs may be effective at reducing hypersensitivity following incision. 
An interesting and surprising observation made in the experiments using the post-
operative pain model is the dissociation between peripherally-restricted KOR mitigation of 
mechanical and not thermal hypersensitivity, especially given the transcriptional profile of KOR-
expressing neurons. The studies described here show that KOR-expressing primary afferents 
have higher levels of several transcripts that have been shown to be involved in heat pain and 
heat hyperalgesia, most noticeably TRPV1. In contrast to what one might predict, peripherally-
 95 
restricted KOR agonists did not have an effect on noxious heat thresholds. This, at first, was 
surprising because KOR agonists decreased behavioral responses to both capsaicin and acetic 
acid, which also have been shown to activate TRPV1. However, we favor the hypothesis that the 
subset of peptidergic neurons that express KOR and high transcript levels of Trpv1 are tuned for 
detection of chemical ligands, rather than for noxious heat stimuli. Even though TRPV1 is most 
commonly associated with detecting and transmitting heat stimuli, this channel is also activated 
by protons, chemical ligands, and can be a transducer downstream of GPCRs (Caterina et al., 
1997). This isn’t to say that these KOR- and TRPV1-expressing neurons don’t respond to heat 
stimuli at all, but their activity pattern and or connectivity pattern when presented with a heat 
stimulus in vivo may not be optimally tuned as a pattern that would lead to noxious heat 
sensation. Instead, activation of TRPV1 on these primary afferents by chemical stimuli may 
instead produce a pattern of activity or activation of a circuit that is more heavily involved in 
transmitting information regarding the chemical milieu of the tissue environment, and perhaps be 
more likely to be involved in generating a burning or stinging sensation. If this were the case, 
one might expect KOR agonists to decrease behavioral responses to chemical TRPV1 agonists 
that have been reported to cause a burning sensation (LaMotte, Shimada, & Sikand, 2011), but 
not to noxious heat.  
Consistent with this idea is a study using the postoperative pain model that showed a 
decrease in tissue pH for several days following incision (Woo, Park, Subieta, & Brennan, 2004), 
indicating that tissue acidosis plays a role in nociception after an incision injury. A study by 
Steen et al. (Steen, Reeh, Anton, & Handwerker, 1992) in rats observed a population of 
cutaneous polymodal C-fibers that responded to low pH application to their receptive fields in 
the skin, and many of the fibers responding to protons also responded to capsaicin indicating 
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they expressed TRPV1. They reported that repeated or longer exposure low pH solutions 
sensitized polymodal C-fibers such that their discharge rate was increased and the von Frey 
thresholds were decreased, and this occurred regardless of whether the C-fibers originally 
responded to low pH solutions. These data are supportive of the idea that KOR-expressing fibers 
are activated and sensitized by molecules that could activate TRPV1 (such as protons) following 
an incision injury, and this could lead to a decrease in mechanical thresholds. KOR agonists 
decrease cAMP through inhibition of adenylyl cyclase (Bruchas & Chavkin, 2010). This would 
limit the phosphorylation of the TRPV1 channel by protein kinase A thereby allowing for 
desensitization of TRPV1 (Pierre et al., 2009). Ion influx and depolarization through TRPV1 
channels can increase release of inflammatory neuropeptides, such as CGRP and SP  (Planells-
Cases, Garcia-Sanz, Morenilla-Palao, & Ferrer-Montiel, 2005). Thus, not only could KOR 
agonists prevent sensitization of KOR-expressing afferents, but they could decrease release of 
inflammatory neuropeptides that would sensitize other afferents (even those that did not respond 
to protons originally).  
Why a KOR-mediated decrease in CGRP and/or SP release would not prevent the 
sensitization of afferents that are involved in heat hyperalgesia is unclear and cannot be resolved 
from the post-operative pain model experiments alone. In cutaneous afferents, studies have 
observed afferent sensitization to heat stimuli, but sensitization to mechanical stimuli after 
injury/inflammation in cutaneous afferents has been rarely observed (Andrew & Greenspan, 
1999); (Banik & Brennan, 2009); (Kirchhoff, Jung, Reeh, & Handwerker, 1990); (Banik, 
Kozaki, Sato, Gera, & Mizumura, 2001); (Du, Zhou, & Carlton, 2006); (Schlegel, Sauer, 
Handwerker, & Reeh, 2004). This has led to the suggestion that mechanical hypersensitivity is 
primarily due to central sensitization in spinal circuits (Schlegel et al., 2004). One possibility is 
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that peripherally-restricted KOR agonists decreased the response of primary afferents to 
mechanical stimulation. This decrease in primary afferent activity could be insufficient to 
activate the sensitized spinal circuits. An alternative or concurrent possibility is that due to the 
higher likelihood of encountering a noxious thermal stimulus in cutaneous tissues, it could be 
that more afferents are tuned for noxious heat detection and more easily sensitized to a heat 
stimulus following injury. Our data suggests that KOR is not expressed on noxious heat-tuned 
afferents, and hence cutaneous KOR-expressing afferents may be in the minority. Even if KOR 
agonists led to these fibers releasing less CGRP and SP, it may not be enough to prevent 
sensitization of non-KOR expressing, noxious heat-tuned afferents (many of which also express 
and release CGRP and SP). 
4.3 POSSIBLE IMPLICATIONS OF HIGHER TRANSCRIPT LEVELS IN KOR-
EXPRESSING AFFERENTS 
An interesting finding of the studies presented here is a deeper characterization of the primary 
afferents expressing KOR. Using IHC and single-cell RT-PCR, we made the observation that the 
subgroup of peptidergic afferents expressing KOR are a unique subset, expressing higher 
transcript levels of the genes encoding for the neuropeptides CGRP and SP, as well as for the 
receptors TRPV1, TrkA, GFRα3, and PGI2R. Higher mRNA levels don’t necessarily always 
translate to higher protein expression, but higher levels of these transcripts could possibly 
indicate that these proteins are playing a prominent role in the function of KOR-expressing 
afferents.  
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Previous reviews based on the use of KOR agonists in preclinical models have 
summarized the effectiveness of opioid agonists, particularly KOR agonists, in reducing pain in 
inflammatory states (Millan, 1990); (Vadivelu et al., 2011). Several factors may contribute to 
this effect, such as increased synthesis and trafficking of these receptors to peripheral afferent 
terminals, larger effects of opioid receptors due to increase of cAMP levels in afferents during 
inflammation, and breakdown of the perineurium that allows for opioid peptide penetration to 
sensory afferents (for review, see (Stein & Zollner, 2009); (Vadivelu et al., 2011)). KOR-
mediated inhibition of VGCC in a subgroup of primary afferents that likely express high levels 
of neuropeptides CGRP and SP, key contributors to neurogenic inflammation, would likely 
decrease the magnitude of neuropeptide release at peripheral terminals and thereby decrease the 
feedback loop in the periphery that is at the core of neurogenic inflammation, present in both 
inflammatory pain and itch states (Grant et al., 2002); (Rosa & Fantozzi, 2013).  
Growth factors and their receptors play a critical role in the development of primary 
afferents early in development, but later in development shift to regulating sensitization of 
afferents, which is common in inflammatory states and after injury (Zhu & Oxford, 2011); 
(Jankowski & Koerber, 2010). KOR-expressing afferents display high transcript levels for 
growth factor receptors TrkA (receptor for nerve growth factor) and GFRα3 (receptor for 
artemin). NGF and artemin have been shown to both sensitize afferents and behavioral responses 
(for review, see (Jankowski & Koerber, 2010)) and also have been shown to potentiate TRPV1 
responses (Ikeda-Miyagawa et al., 2015); (S. A. Malin et al., 2006) – Trpv1 being a transcript 
that was also significantly elevated in KOR-expressing neurons. Thus, KOR-mediated inhibition 
of these neurons in particular could be a contributing factor as to why KOR agonists are 
particularly effective in reducing pain in inflammatory states. Future studies could investigate 
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KOR-expressing afferents innervating different tissue types and how their responses are changed 
by different growth factors. Even though our results show a similar pattern of Grfα3 and Trka 
transcript expression in KOR-cre saphenous and femoral afferents, previous work has shown that 
muscle and cutaneous afferents show different levels of sensitization to artemin and NGF (S. 
Malin et al., 2011). It would be interesting to compare sensitization of KOR-expressing muscular 
and cutaneous afferents to different growth factors. This type of experiment could help to test 
whether the similar transcriptional profile of KOR-expressing afferents indicates these afferents 
are involved in detecting like stimuli across tissue types.  
Another contributing factor to the effectiveness of KOR agonists in inflammatory states 
is higher expression of Ptgir, the transcript for the prostacyclin (PGI2) receptor. Similar to PGE2, 
PGI2 is also involved in generation of inflammatory states and pain sensitivity. PGI2R knockout 
mice demonstrate decreased vascular permeability and paw volume following injection of 
algogens bradykinin or carrageenan, respectively. These knockout mice showed decreased 
nociceptive responses in the acetic acid writhing test suggesting a role for this receptor in 
inflammation and pain generation (Murata et al., 1997). As the PGI2 receptor is expressed on 
peripheral tissues, such as blood vessels (Myren, Olesen, & Gupta, 2011), as well as primary 
afferents (Oida et al., 1995), it is like the cellular mechanisms underlying the effect prostacyclin 
and its receptor during inflammatory pain is complex and involves multiple tissue types. 
However, KOR-mediated inhibition of primary afferents expressing this receptor would likely 
play a part in decreasing sensitization but also decreasing activation following inflammation or 
injury, as PGI2 receptor activation has been shown to increase adenylyl cyclase activity and 
cAMP production (Nakae et al., 2005). Targeting primary afferents expressing the PGI2 receptor, 
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therefore, may be helpful in reducing ongoing pain in addition to evoked pain following an 
injury.  
4.4 A POTENTIAL ROLE FOR KAPPA OPIOIDS IN THE REGULATION OF LOW-
THRESHOLD MECHANOSENSATION 
One of the more surprising and novel findings of the experiments described here is the 
expression of KOR in several subtypes of LTMRs. We found that some NF200-positive 
lanceolate and circumferential endings targeting hair follicles in the hind paw and back skin 
express KOR. Circumferential endings have been identified and described as two subtypes, those 
expressing NF200 and those expressing CGRP (Abraira & Ginty, 2013); (Bardoni et al., 2014). 
Bai et al. (Bai et al., 2015) used a genetic mouse model to identify and characterize the NF200-
expressing subset of primary afferents that form circumferential endings. The authors show that 
these afferents respond preferentially to skin stroking but are unresponsive to hair deflection, and 
encode skin deflection into the noxious range. In contrast, lanceolate endings respond 
preferentially to hair deflection and non-noxious skin indentation (Bai et al., 2015); (Rutlin et al., 
2014). NF200-expressing circumferential endings are also among the most expansive in terms of 
the region of skin innervated by a single afferent, and can up to 180 circumferential endings in 
the skin, up to 3mm2 area of skin (Bai et al., 2015). NF200-expressing afferents forming 
lanceolate endings innervate fewer hair follicles and a smaller area of skin (Bai et al., 2015). This 
suggests that, even if only a small number of these subtypes of LTMRs express KOR, these 
afferents could innervate a relatively large area of skin and number of hair follicles. Therefore, 
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KOR signaling could have a larger effect on the transmission of low-threshold mechanosensation 
in the hairy skin than the number of LTMR afferents would suggest.  
The next question, of course, is what effect KOR signaling would have on LTMRs and 
the implications of this signaling for mechanosensation. One possibility is that the kappa opioid 
system is regulating the overall course-scale sensitivity of the skin to stimulation opposed to 
fine-scale modulation of an individual aspect of low-threshold mechanosensation. We show that 
KOR agonist dynorphin decreases evoked-EPSCs in lamnia III after optogenetic activation from 
KOR-expressing primary afferents, and lamina III is part of the LTMR-recipient zone (Abraira et 
al., 2017). Further studies are needed to definitively show that KOR agonists decrease 
neurotransmitter release from LTMRs (discussed below in Section 4.5). However, dynorphin 
signaling in the spinal cord could act as a gain control mechanism for low-threshold 
mechanosensation. Dynorphin could modulate the sensitivity of LTMR inputs into the spinal 
cord depending upon the context of incoming signals such that the organism can extract the 
relevant information in given environmental and physiological contexts. This type of modulation 
has been studied in multiple sensory systems (Nikolaev, Leung, Odermatt, & Lagnado, 2013); 
(Robinson & McAlpine, 2009) and several recent papers have investigated this type of gain 
control modulation by dopamine in the olfactory bulb (Banerjee et al., 2015); (Vaaga, Yorgason, 
Williams, & Westbrook, 2017).  
One context in which a potential gain control role of kappa opioid signaling on low-
threshold mechanosensation would be useful is mechanical allodynia. There is a previous report 
in the literature characterizing DOR expression in LTMR subgroups which led to the speculation 
that DOR agonists may be effective in the treatment of mechanical allodynia (Bardoni et al., 
2014). Together these data suggest a conceivable role of the opioid receptor system in the 
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regulation of mechanical sensitivity. One possibility is that after injury, opioid signaling in the 
dorsal horn is elevated in an effort to decrease excitability such that the pain sensation is still felt 
(to protect from further tissue damage), but not to the extent that the animal cannot function (in 
case it still needs to run away from a predator). However, it seems that this type of modulation is 
a delicate balance, as elevated dynorphin levels in the spinal cord following injury can also 
exacerbate sensitivity (Laughlin et al., 1997); (Koetzner, Hua, Lai, Porreca, & Yaksh, 2004). 
4.5 THE ROLE PERIPHERAL KOR SIGNALING HAS ON MODULATION OF 
ITCH AND PAIN 
We found that optogenetic activation of KOR-cre afferents caused behaviors consistent with 
nocifensive withdrawal, but did not elicit scratching behaviors, and that KOR agonists decreased 
capsaicin-induced licking of the hind paw. These data seems in contrast with a previous report 
from our laboratory that included an experiment testing the effect of systemically administered 
nalfurafine on itch- and pain-related behaviors (Kardon et al., 2014) using the cheek model 
(Shimada & LaMotte, 2008). In this experiment, either the pruritogen chloroquine or the algogen 
capsaicin was injected intradermally into the cheek and the number of scratch bouts (indicative 
of itch-related behavior) or wipes (indicative of pain-related behavior) was quantified. The 
results showed that nalfurafine significantly decreased the number of scratch bouts caused by 
both chloroquine and capsaicin, but had no effect on the number of wipes induced by either 
chemical. This was interpreted as KOR agonists having a specific effect on itch, but not pain. In 
contrast, the experiments described here demonstrate that systemically administered nalfurafine, 
as well as peripherally-restricted ICI204,488 and FE200665, decreased the time spent licking the 
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hind paw following intraplantar injection of capsaicin which is interpreted as KOR agonist-
mediated decrease in pain-related behaviors.  
The question is why nalfurafine would decrease pain behaviors in one assay but not in the 
other, and there are several possible explanations. The first possibility is the location of the 
capsaicin injection, one being intradermal and primarily affecting cutaneous fibers, and the other 
being intraplantar which could affect cutaneous afferents but also afferents targeting deeper 
tissues, such as the muscle. It could be that KOR-expressing fibers targeting the skin are more 
tuned for pruritogens than for algogens, and KOR-expressing fibers targeting deeper tissues are 
more tuned for algogens. Although the KOR-cre neurons backlabeled from the saphenous nerve 
showed a similar pattern of transcripts to those backlabeled from the muscle, it could be that the 
cutaneous KOR-expressing fibers also express other proteins that would tune them for 
pruritoception, such as the chloroquine receptor Mrgpra3. However, this is not what was 
observed in the experiments described here, as only one of the KOR-cre neurons expressed 
MrgprA3 mRNA. The sample size in this experiment was relatively small, though (n=9 cells), 
and so this doesn’t exclude the possibility that some cutaneous KOR-expressing cells also 
express Mrgpra3. Nevertheless, the data collected thus does not suggest that cutaneous KOR-
expressing fibers are specific for itch but other experiments would be necessary to arrive at a 
more definitive conclusion. Further, nalfurafine would be acting at both peripheral and central 
KORs, not only at peripheral KORs. Other experiments described here, in addition to others (Y. 
Wang et al., 2005); (Inan & Cowan, 2004); (Suzuki et al., 2004); (Endoh et al., 2001), 
demonstrate that nalfurafine decreases itch- as well as pain-related behaviors and therefore is 
consistent with the interpretation that KOR agonists do not specifically modulate itch sensation.  
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An alternative and / or contributing factor could be that itch is under strong modulatory 
control, especially within dorsal horn circuits. Loss of B5-I neurons in bhlhb5 mutant mice 
caused exacerbated itch such that mice developed lesions from excessive scratching and 
grooming (S. E. Ross et al., 2010). One of the two subsets of B5-I neurons are inhibitory 
interneurons that also express the endogenous KOR agonist dynorphin (Kardon et al., 2014). 
This suggests the possibility that loss of one component of modulatory controls in the spinal cord 
regulating the processing of itch sensation has dramatic consequences. Therefore, any 
modulation of this control by exogenous KOR agonists would have a stronger and perhaps more 
noticeable impact on itch-related behaviors than pain-related behaviors.  
It could also be that intraplantar injection into the hind paw causes itch and/or pain 
sensation, but that mice cannot scratch their hind paw so we interpret the behavior as licking, a 
nocifensive behavior. In the present experiment, we did not attempt to distinguish between 
licking and biting of the hind paw, which could be an indication of itch compared to pain and is 
used this way in the calf model (Shimada & LaMotte, 2008). Another possibility is that there 
could have been some methodological inconsistencies in the previous experiment reported in the 
Kardon et al. (2014) paper. The behavior that is considered wiping in response to the injected 
chemical is very specifically described in the original report of the model (Shimada & LaMotte, 
2008). If one was not very careful and observant while scoring the experiment, grooming 
behavior and/or a scratching-like of behavior with the forelimb could be mistakenly counted as 
wiping behavior, thus leading to an overestimation of the number of wipes caused by a chemical 
and masking an effect (if there was one). One or all of these alternatives could contribute to the 
differences observed between Kardon et al. (2014) and the experiments reported here.  
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4.6 FUTURE DIRECTIONS 
4.6.1 Developmental KOR expression 
Using both a cre-dependent allele and a cre-dependent virus in combination with the KOR-cre 
allele, we could carefully characterize the cell types expressing KOR throughout development. If 
KOR-expressing afferents were labeled from embryonic development through adulthood, 
approximately one third of the lumbar DRG afferents in the adult showed KOR-cre labeling, and 
a similar proportion of the DRG afferents in the adult showed KOR-cre labeling if afferents were 
labeled early in postnatal development (at P1). However, if KOR-expressing afferents were 
labeled during adulthood, a smaller proportion of the total lumbar DRG afferents showed 
labeling such that it was similar to the 9% of DRG neurons expressing KOR that was previously 
reported by Ji et al. (1995). While cre-dependent viral labeling approaches are not 100% 
efficient, the dual FISH experiments showed that it is possible to label upwards of 90% of 
Oprk1-expressing afferents using this approach. Together these data suggest that KOR is more 
widely expressed during early stages of development up to at least the early postnatal days, and 
then expression is decreased such that fewer afferents express KOR in the healthy adult mouse. 
The downregulation of KOR expression in DRG afferents is not completely unexpected, 
as many genes show different patterns of expression throughout development. In the DRG, for 
example, TRPV1 is more widely expressed early in development such that both peptidergic and 
non-peptidergic C-fibers express TRPV1 early and this expression is narrowed to a subset of 
peptidergic fibers in adulthood (Cavanaugh et al., 2011). Previous studies investigating MOR 
and DOR immunoreactivity in the rat DRG across development also observed a decrease in the 
percentage expressing these proteins by approximately 10% from P3 to P21. This decrease was 
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most notable in NF200-expressing cells and in adulthood almost all MOR and DOR-expressing 
afferents were restricted to small and medium diameter neurons (Beland & Fitzgerald, 2001); 
(Nandi et al., 2004). Together, this study and the results of our experiments support the idea that 
the opioid system plays different roles in modulating somatosensory information in neonatal 
development versus adulthood. Consistent with this idea, Nandi et al. (2004) investigated the 
effects of MOR agonists on analgesia in neonate versus adult animals and report that the potency 
of morphine is higher in neonates than adults, particularly for mechanical stimulation.  
Some evidence suggests that KOR agonists may have a similar effect; Barr et al. (Barr et 
al., 2003) report that an intraplantar injection of KOR agonist U50,488 reduced nocifensive 
behavior in the formalin test in rats at P3 and P21. Further studies would be necessary to confirm 
this effect using different agonists, as U50,488 also has some affinity for voltage-gated sodium 
channels (Joshi et al., 2003). Yet, using peripherally-restricted KOR agonists instead of 
centrally-penetrant drugs such as morphine in the treatment of pain for infants is appealing 
because they likely would have fewer side effects. Peripherally-restricted KOR agonists could 
also have the benefit of a smaller impact on the development of central circuits. A recent report 
found that repeated morphine injections in rats decreased the potency of the anesthetic lidocaine, 
which is used in surgical procedures (Liu & Gold, 2016). Whether a similar effect on lidocaine 
potency is observed when using a KOR agonist would be an interesting next step, and extending 
this type of study to include neonates and adults could better increase the understanding of post-
surgical pain treatment.  
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4.6.2 KOR expression in primary afferents after injury 
Our study focused on characterizing KOR-expressing primary afferents in naive adult mice and 
found that at least two distinct groups of primary afferents express KOR. However, we did not 
investigate how KOR expression in primary afferents changes after injury. Several studies have 
reported increases in Oprk1 mRNA expression or KOR protein expression in a model of 
neuropathic pain (Caram-Salas et al., 2007), after PGE2-induced inflammation (Zambelli et al., 
2014), or after CFA-induced inflammation (Puehler et al., 2006); (Obara et al., 2009). Now that 
the subset of primary afferents expressing KOR have been characterized in more detail, it would 
be interesting to determine if the increase in KOR expression after injury is due to an 
upregulation in the same afferents expressing KOR in a naïve state, if KOR expression is 
induced in a different subset(s) of primary afferents, or both. Because we saw a decrease in the 
proportion of afferents expressing KOR from early development to adulthood, it would be 
interesting to test whether or not primary afferents that expressed KOR at one point in 
development are more likely to induce KOR expression after an injury.  
In the studies described here, we did not observe overlap of KOR with TRPM8 and 
therefore did not test the effects of KOR agonists on cold sensitivity. Interestingly, though, a 
recent study from the McKemy lab found that GFRα3 KO mice showed selective reductions in 
cold allodynia in models of inflammatory, neuropathic, and chemotherapy-induced pain (CPN) 
(Lippoldt, Ongun, Kusaka, & McKemy, 2016). This lab has previously described artemin, 
GFRα3 ligand, induces sensitization to cold stimuli in a TRPM8-dependent manner (Lippoldt, 
Elmes, McCoy, Knowlton, & McKemy, 2013). We did not observe overlap of KOR-cre and 
TRPM8-IR, nor did any of the Oprk1 positive neurons express Trpm8 mRNA. One would 
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predict that peripherally-restricted KOR agonists would not affect cold pain or cold 
hypersensitivity, but it could be that neurons expressing GFRa3 and TRPM8 could express KOR 
after injury and therefore KOR agonists may alter processing of cold in an injured state. The 
effect of KOR agonists on cold responsive primary afferents in naïve states and after tissue 
injury, as well as behavioral responses, remains to be tested.  
4.6.3 Testing the effects of dorsal horn presynaptic KORs in response to natural stimuli 
or in specific neuronal subtypes 
In this study, we found that KOR agonist dynorphin decreased light-evoked EPSCs from KOR-
cre primary afferent terminals in neurons in both lamina I and lamina III or the dorsal horn. 
Terminals in these laminae are also more likely to be functionally distinct in that afferents 
targeting lamina I are more likely to transmit nociceptive information and those in deeper lamina 
(II-V) are more likely to transmit low-threshold mechanosensation. However, this conclusion 
cannot be definitely reached without more specific experiments. Future studies using the ex vivo 
skin-nerve-spinal cord preparation or in vivo recordings targeting lamina I neurons could 
determine the effect of KOR agonists on presynaptic release caused by natural stimulation of the 
skin. Considering the results of the behavioral assays, it would be interesting to compare the 
effect of spinally administered KOR agonists on presynaptic release when using chemical 
algogens, chemical pruritogens, or noxious thermal stimuli. If KOR agonists don’t have an effect 
on presynaptic release caused by thermal stimuli, it could be that thermal sensitivity is being 
modulated by the kappa opioid system at a level other than the primary afferents.  This 
separation between the effect of peripheral and central kappa system in regulating a particular 
modality of nociception would be an interesting concept to explore in the future as the 
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modulation of somatosensation by the opioid system throughout the pain pathway continues to 
be explored. 
As it is would be difficult to access dorsal horn neurons in lamina III in a whole spinal cord 
recording, a possible way to more specifically test the effect of KOR agonists on glutamate 
release from LTMR central terminals is to use the spinal preparation developed by Yu Omori 
(and described in Chapter 3) in combination with genetic mouse lines. The laboratory of David 
Ginty has developed several mouse lines that specifically target subtypes of hair follicle 
afferents. Using optogenetics to activate particular hair follicle types, such as myelinated 
circumferential afferents (Bai et al., 2015) and either Aβ or Aδ lanceolate endings (L. Li et al., 
2011); (Rutlin et al., 2014). 
4.6.4 Possible ways to test the effects of KOR agonists on behavior driven by low-
threshold mechanosensation 
In our studies, we focused on the effect of centrally-penetrant and peripherally-restricted KOR 
agonists primarily on behaviors elicited by aversive stimuli, such as injection of a noxious 
chemical or exposure to a noxious heat source. Behavioral studies investigating the low-
threshold mechanosensation have mainly been focused on the glabrous skin, such as the von 
Frey test and dynamic mechanical sensation assay (Duan et al., 2014). However, there are very 
few hairs on the ventral footpad of the mouse making it difficult to assess the contribution of 
LTMRs innervating the hairy skin to behavioral responses to begin understanding how the 
activity of these afferents contribute to the sensation generated. A few tests have been designed 
to test how low-threshold mechanosensation is altered in mice with genetic mutations. An altered 
version of the sticky tape assay was used to test the effects that knockout of the 
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mechanosensitive ion channel Piezo2 had on mice’s perception of the tape stuck to their back 
(Ranade et al., 2014). The authors found that Piezo2 knockout mice showed fewer attempts to 
remove the tape (i.e., less licking and scratching) than wild-type littermates and interpret this as a 
decrease in sensitivity to low-threshold mechanosensation. However, as the Piezo2 knockout 
mice also showed deficits in proprioception, it is unclear if this result was truly a measure of 
low-threshold mechanosensation or the agility of the mice compared to controls and this 
particular assay would need to be further validated. 
One other model that could be used to test the effects of KOR signaling on low-threshold 
mechanosensation, originally developed to test sensory integration in a mouse model of autism, 
is the tactile pre-pulse inhibition (Tactile PPI) assay (Orefice et al., 2016). In this assay, a light 
puff of air is given as a pre-pulse ‘warning’ that acts to dampen the startle response to a loud 
tone. Mice that have been shaved and received lidocaine injection (to block primary afferent 
activity) do not show this dampening of the startle response, suggesting that the tactile pre-pulse 
is dependent on the activity of the primary afferents responding to the air puff; these afferents 
have previously been shown to be those that form lanceolate endings (Bai et al., 2015); (Rutlin et 
al., 2014). KOR-expressing neurons form lanceolate endings, which would respond to the air 
puff pre-pulse, but they also form circumferential endings which would not respond to the air 
puff. Thus, it is unclear if KOR expression on lanceolate endings alone would be strong enough 
to drive a change in sensitivity to the air puff. Studies using the Tactile PPI experimental 
paradigm or variations of this assay would be interesting to explore in the future. 
While a mouse may not the best model system to investigate the hairy LTMR system, it 
does offer a way to investigate the cellular and circuit mechanisms that is not afforded by other 
systems. The best approach may be to test the effect of peripherally-restricted KOR agonists on 
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low-threshold mechanosensation in humans that can report and describe the sensation they are 
experiencing, though, and then study possible mechanisms in a mouse model.  
4.6.5 Investigating interactions between the kappa opioid system and the immune system 
In the studies described here, we characterize the primary afferent nerves that express the KOR, 
and use exogenous KOR agonists to test the effect of KOR signaling on pain and itch behaviors. 
We find that peripherally-restricted KOR agonists are sufficient to decrease behavioral responses 
after injection of chemical algogens or pruritogens, as well as mechanical hypersensitivity after 
an incision injury. These results are consistent with the pattern of KOR expression on primary 
afferent nerves, and one highly likely site of action for KOR agonists, especially the 
peripherally-restricted KOR agonists, is on the peripheral terminals of primary afferent nerve 
fibers. Another possibility, however, is that the KOR agonists are acting also at KORs expressed 
on immune cells. Endogenous opioid peptides have been shown to be released by infiltrating 
immune cells following an injury, including beta-endorphin and dynorphin, that are thought to 
contribute to endogenous analgesia, at least in part, on opioid receptors on primary afferents 
(Rittner et al., 2001); (Stein, Hassan, Lehrberger, Giefing, & Yassouridis, 1993); (M. Schafer, 
Carter, & Stein, 1994); (Cabot, Carter, Schafer, & Stein, 2001). However, there is some evidence 
that KORs are expressed by certain types of immune cells. Some studies have shown KOR 
expression on lymphocytes (Gaveriaux et al., 1995); (Chuang et al., 1995) and that activation of 
these receptors can alter antibody responses (Guan, Townsend, Eisenstein, Adler, & Rogers, 
1994); (Gaveriaux-Ruff, Simonin, Filliol, & Kieffer, 2003). Other studies from the Machelska 
laboratory have shown that approximately one third of leukocytes infiltrating the area of a nerve 
injury release endogenous opioid peptides (Labuz et al., 2009),. They also report that exogenous 
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opioid agonists can cause release of endogenous opioid peptides from leucocytes, and that 
leucocyte depletion decreases the analgesic effects of exogenous opioid agonists in a model of 
neuropathic pain (Celik et al., 2016). These results suggest that opioid receptors on immune cells 
could play an important role in the analgesic or antipruritic effects of exogenous opioid receptor 
agonists.  
As several of the behavioral assays used here are likely to induce an inflammatory 
response, it is possible that KOR on infiltrating immune cells could contribute to the effects of 
KOR agonists. One possible way to dissociate the contributions of KOR on primary afferents 
and immune cells would be to knockout KOR in each cell type measure the effects of KOR 
agonists in behavioral assays of acute itch and pain. To do so, the floxed KOR allele could be 
used, in which the KOR gene is surrounded by loxP sites, and this mouse could be crossed to a 
mouse line that expresses cre either in primary afferents or in immune cells. A recent study using 
a conditional knockout (cKO) of the MOR in Nav1.8-expressing sensory neurons (primarily C-
fibers) reported that cKO mice showed reduced opiate-induced analgesia compared to wild-type 
controls (Weibel et al., 2013). These data suggest that MORs on primary afferents play a critical 
part in exogenous opioid agonist-induced analgesia. Overall, it is likely that KORs expressed on 
both the nervous system and the immune system contribute to the decrease in pain or itch 
behavior observed after KOR agonist treatment. Understanding this interaction and the 
contribution of KOR signaling within each system to analgesia / antipruritus could help advance 
treatments. The murine immune system is quite different than the human immune system 
(Mestas & Hughes, 2004) and so results from these experiments should be interpreted with 
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